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CHAPTER I 
 
PURPOSE OF STUDIES DESCRIBED IN THIS DISSERTATION 
 
The work described in this dissertation focuses on the plasma protein factor XI 
(FXI), which is the zymogen of a protease, called factor XIa (FXIa), that contributes to 
blood coagulation. For this project, we investigated the role of FXI in the mortality and 
pathophysiology of murine sepsis.  We hypothesized that FXI contributes to mortality during 
sepsis, and that it influences both the coagulopathy, as well as the inflammatory response, 
that occurs during sepsis.  To test our hypotheses, we induced polymicrobial sepsis in mice 
using the cecal ligation and puncture (CLP) model to fulfill three Specific Aims.  For Aim 1, 
we evaluated the contribution of FXI to survival during sepsis by comparing FXI deficient 
(FXI-/-) mice to their wild-type (FXI+/+) and FXI+/- littermates.  We determined survival for 
each genotype over a period of 7 days after CLP.   To fulfill Aim 2, we explored the role of 
FXI on the activation of coagulation in mice after CLP.   We collected blood and tissue from 
FXI-/- and FXI+/+ littermates sacrificed at several time points after CLP to evaluate systemic 
and histologic markers of coagulopathy over time.  For Aim 3, we assessed the role of FXI 
on the inflammatory response to CLP by looking at markers of inflammation in blood and 
tissue from FXI-/- and FXI+/+ mice.  Chapter V describes our findings for these experiments, 
as well as the results of additional in vitro and in vivo experiments that further investigated 
the influence of FXI on the pro-inflammatory contact activation system.  Our data provide 
novel insight into the influence of FXI on coagulation and inflammation, and suggest there 
are therapeutic advantages to targeting FXI for the treatment of patients who suffer from 
pathologies arising from each system. 
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CHAPTER II 
 
REVIEW OF COAGULATION 
 
Introduction to the Thesis Project 
  Formation of the plasma enzyme thrombin is critical for normal formation of a 
blood clot (hemostasis). Thrombin generation is beneficial when generated locally to seal 
damaged blood vessels during hemostasis, but may contribute to pathology when generated 
inappropriately during thrombosis.  Thrombin is the product of a series of reactions 
involving several plasma serine proteases and their cofactors.  One of these proteases, factor 
FXIa, is generated from its precursor FXI by the protease factor XIIa (FXIIa), or by 
thrombin itself.  FXIa contributes to thrombin generation by cleaving factor IX (FIX) to 
form the protease factor IXa (FIXa).  Epidemiologic data indicate that FXI makes a 
disproportionately greater contribution to thrombosis than to hemostasis in humans.  These 
data, bolstered by studies with animal models that utilize FXI deficient mice, have led to the 
development of FXI inhibitors, which may be safer alternatives for anticoagulant therapy.  In 
addition to being a valuable tool for determining the role of FXI in hemostasis and 
thrombosis, studies with FXI-/- mice are also providing clues about the role of FXI during the 
host response to invading micro-organisms.  These studies, combined with in vitro findings, 
highlight several unique features of FXI that place it at a junction between coagulation and 
inflammation.  In this project, I evaluated the effect of FXI on the coagulopathy and 
inflammatory response during the crucial early stages of murine sepsis. 
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Introduction to Plasma Coagulation 
 The plasma coagulation system is a tightly regulated host response mechanism that 
minimizes blood loss after vascular injury through formation of a fibrin and platelet-rich clot 
(Dahlback 2000). Blood clots result from an interaction between subendothelial collagen, 
platelets, and numerous proteins within blood plasma.  Clot formation begins when 
circulating platelets near a vascular lesion attach to exposed subendothelial collagen.  This 
attachment is mediated by von Willebrand factor, a multimeric glycoprotein that tethers 
platelets to collagen by binding to glycoprotein (GP) Ib of the platelet GPIb/IX/V receptor 
complex (Ruggeri and Mendolicchio 2015).  Platelets are then activated through several 
mechanisms, and bind to each other through a process called aggregation.  Platelet adherence 
and subsequent aggregation on transected vessels occurs within 30 seconds after injury 
(Weiss and Lages 1988).  In addition to forming a vital platelet plug to staunch bleeding, this 
initial stage of hemostasis sets the conditions for effective fibrin formation, which is 
essential for clot integrity and stability.  Phospholipids, which are expressed by activated 
platelets and damaged endothelial cells, provide a scaffold for the cell surface reactions that 
result in fibrin formation (Davie, Fujikawa et al. 1991), while activated platelets secrete 
factors that support the process (Monroe and Hoffman 2014).  Vascular damage also exposes 
molecules that trigger the fibrin-forming plasma coagulation system, a set of enzymatic 
reactions that result in generation of thrombin.  Thrombin converts soluble fibrinogen into 
insoluble fibrin and contributes to platelet activation.  One of the plasma enzymes that 
contribute to thrombin generation is the protease FXIa, the subject of my thesis work.   
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Models of Plasma Coagulation 
 The plasma reactions that result in thrombin generation and subsequent fibrin 
formation at a wound site involve a group of proteins that are known as coagulation factors.  
With the exception of fibrinogen (the precursor of fibrin), these proteins are either zymogens 
of serine proteases, or inactive cofactors that facilitate coagulation reactions on surfaces 
(Monroe and Hoffman 2014).  Most coagulation factors are designated by a Roman numeral, 
and are numbered according to their order of discovery.  The active form of each factor is 
indicated by a lowercase “a” to the right of the Roman numeral, or is referred to by name.  
The zymogens are prothrombin (factor II, precursor of thrombin), prekallikrein [PK, 
precursor of α-kallikrein (α-kal)], and factors VII, IX, X, XI, and XII.  The cofactors are 
high molecular weight kininogen (HK), tissue factor (TF), and factors V and VIII.  A 
process for fibrin generation was first introduced in two separate publications in 1964.  Both 
papers proposed the same mechanism, but Macfarlane called it a “cascade” (Macfarlane 
1964), while Davie and Ratnoff called it a “waterfall” (Davie and Ratnoff 1964).  Figure 1 
shows a version of the original cascade model, which is the basis for the in vitro prothrombin 
 
Figure 1.  Cascade model of plasma 
coagulation.  Fibrin generation is the result of a 
sequence of enzymatic reactions in plasma.  The 
process is initiated through intrinsic (white 
arrows), or extrinsic (black arrow) pathways.  Both 
pathways result in activation of FX to FXa, 
triggering a common pathway (grey arrows) for 
fibrin formation.  In the cascade model, FXI is 
activated by FXIIa.  However, FXII, PK, and HK 
(enclosed in gray box) deficient patients do not 
have a bleeding disorder.   This raises questions 
about the role of these proteins in coagulation in 
vivo, and suggests there are other mechanisms 
(indicated by the “?” symbol) for FXI activation. 
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time (PT) and activated partial thromboplastin time (aPTT) clotting assays.  The model 
illustrates a series of reactions wherein a zymogen is converted to an active protease, which 
then acts upon the next zymogen in the cascade until prothrombin is converted to thrombin 
by the protease FXa.  According to the cascade model, there are two distinct biochemical 
pathways for thrombin generation.  In the intrinsic pathway, the basis for the aPTT assay, 
FXII is activated on a surface in a process that also involves PK and HK.   The resulting 
FXIIa then activates FXI to complete a set of reactions that are collectively referred to as 
contact activation (Figure 2).  Contact activation triggers the sequential activation of FIX, 
FX, and prothrombin.  In the extrinsic pathway, the basis for the PT assay, tissue factor (TF) 
binds to factor VII (FVII), forming a TF/FVII(a) complex that subsequently activates factor 
X (FX).  The aPTT and PT clotting assays are useful for detecting deficiencies of clotting 
factors in plasma because factor-deficient plasmas clot more slowly than normal plasma in 
vitro.  In many cases, this in vitro phenomenon is translated to the clinical setting, wherein 
 
Figure 2.  Contact Activation. On a surface (gray disk) FXII is auto-activated to form FXIIa (1). FXIIa activates PK to generate -kal (2), which reciprocally activates additional FXII (3).   -kal also cleaves HK to liberate BK (4).  FXIIa activates FXI (5) to propagate coagulation. The cofactor HK (shown in red) facilitates FXI and PK binding to the surface.  
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patients with a deficiency of a clotting factor will exhibit a clotting defect and therefore tend 
to bleed.  However, this is not always the case.  For example, patients with a hereditary 
deficiency of FXII, PK, or HK have a markedly prolonged aPTT, but no bleeding disorder, 
while patients with a deficiency of FXI, the substrate for FXIIa in the cascade model, have a 
prolonged aPTT and may bleed excessively, but only in certain instances.  This places the 
role of contact activation in hemostasis in doubt, and suggests there are other mechanisms 
for FXI activation in vivo.     
Advances in coagulation research have resulted in a revised model of thrombin 
generation (Figure 3) that excludes proteins that are not required for hemostasis (FXII, PK, 
and HK).  This model proposes that tissue factor is the initiator of thrombin generation in 
vivo, based upon clinical observations and in vitro work showing that (a) in addition to 
activating FX, the TF/FVIIa complex also activates FIX (Osterud and Rapaport 1977), and 
(b) thrombin activates FXI (Gailani and Broze 1991, Naito and Fujikawa 1991).  According 
to the revised model, thrombin generation is initiated after vascular injury exposes tissue 
X
IX
IXa
VIIIa
VIIa
Vessel
Injury
TF
Thrombin
X
Xa
Prothrombin
Va
XI
IX
XIa
TFPI
Fibrinogen Fibrin
 
Figure 3. Revised model of plasma 
coagulation.  Vascular injury exposes TF 
to FVII, and the resulting TF/FVIIa 
complex initiates thrombin generation by 
activating FX to FXa.  The activation of 
FX by TF/FVIIa is limited by Tissue 
Factor Pathway Inhibitor (TFPI) (red 
arrow), so that sustained thrombin 
generation depends upon activation of 
FIX by TF/FVIIa.  FXIa activates FIX 
(grey arrows) to provide additional 
thrombin to offset TF/FVIIa inhibition.  
In the revised model, FXI is activated by 
thrombin.  For both figures, zymogens 
and proteases are shown in black.  When 
Roman numerals are used, the active 
protease is designated by the letter “a.”  
Cofactors are shown in blue. 
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factor (TF), an integral membrane protein on the surface of a variety of non-vascular cells, to 
the circulation (Dahlback 2000, Morrissey 2004, Gailani and Renne 2007).  TF quickly 
binds to zymogen FVII within the circulation forming a 1:1 complex.  This interaction on the 
surface of cells allows a variety of plasma proteases to convert zymogen FVII to its active 
form, FVIIa (Davie, Fujikawa et al. 1991, Furie and Furie 1992, Monroe and Key 2007).  
The TF/FVIIa enzyme complex then binds and activates FX to FXa, which, in a reaction that 
is accelerated by the cofactor FVa, converts the plasma zymogen prothrombin to active 
thrombin.  FX is also activated by FIXa, which is primarily produced by cleavage of FIX by 
the TF/FVIIa complex.  Efficient activation of FX by FIXa requires the cofactor factor VIIIa 
(FVIIIa).  The activation of FIX by TF/FVIIa is an important mechanism for supporting 
thrombin generation because the initiating pathway (activation of FXI by TF/FVIIa) is 
inhibited by the Kunitz-type protease inhibitor tissue factor pathway inhibitor (TFPI) (Broze 
and Girard 2012, Monroe and Hoffman 2014).   In the revised model, the protease FXIa, 
generated by the cleavage of zymogen FXI by thrombin (and FXIa), completes a positive 
feedback loop for thrombin generation by activating FIX (Gailani and Broze 1991, 
Borissoff, Spronk et al. 2009).  Thus, FXIa functions in clot maintenance, after thrombin 
generation is first initiated via the “tissue factor pathway”.  This current understanding of the 
role of FXI, which is illustrated by the revised model (Figure 3), helps explain why FXI 
deficiency contributes to abnormal bleeding in some patients (described in Chapter III), and 
why FXII and HK-deficient individuals appear clinically normal.  It also illustrates why the 
revised model currently is the more clinically relevant representation of hemostasis. 
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Coagulant mechanisms have been described as operating along a clinical spectrum, 
with hemostasis at the center of a delicate balance (Figure 4).  Inadequate coagulation 
results in hemorrhage (bleeding), while excessive or inappropriate coagulation results in 
thrombosis (blood vessel occlusion).  Several therapeutic strategies are employed to treat 
and/or prevent disorders that represent each extreme of the coagulation spectrum, based 
upon the premise that thrombosis and hemorrhage result from a dysregulation of normal 
hemostasis.  Consequently, in most cases, a therapy that is intended to treat a disorder at one 
end of the spectrum carries the risk of causing a disorder at the opposite extreme of the 
spectrum.  In the case of anticoagulant therapy for prevention of thrombosis, treatment per 
the current paradigm carries the unfortunate risk of severe bleeding because traditional 
anticoagulants target proteins such as thrombin and FXa that are vital for hemostasis.  For 
this reason, much of the effort in coagulation research is focused on the development of 
Figure 4.  Current theory of coagulant mechanisms.  Current treatment strategies place hemostasis 
at the center of a physiologic balance between hemorrhage and thrombosis.  
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novel anticoagulants that have reduced bleeding side effects.  As will be discussed in 
Chapter 2, FXI has emerged as a target for such therapies because of its relatively minor role 
in hemostasis. 
 
Cross-Talk Between Coagulation and Inflammation  
The coagulation system functions alongside other host defense systems, including 
inflammation.  Inflammation is a host response to injury that, when directed against 
microorganisms, is a key component of innate immunity (Tizard 2008).   Many (perhaps 
most) clinical situations involve “cross-talk” between coagulation and inflammation (Levi, 
Keller et al. 2003, Levi and van der Poll 2010, van der Poll, de Boer et al. 2011, van der Poll 
and Levi 2012).  The two systems are often activated by a common stimulus (Markiewski, 
Nilsson et al. 2007), and each pathway modulates the other through a variety of mechanisms 
to restore normal physiologic function after an insult.  Like coagulation, inflammation 
operates along a clinical spectrum.  Localized inflammation of an appropriate intensity is at 
the center of the balance, and results in microbial elimination and tissue repair.  At the 
extremes are inadequate inflammation, which may contribute to microbial dissemination, 
and overwhelming inflammation, which manifests as an infection-induced systemic 
inflammatory response syndrome, or sepsis.  Thus, the interaction between coagulation and 
inflammation, which is normally beneficial, contributes to increased morbidity and mortality 
during sepsis.  This interaction presents many challenges for sepsis therapy.  For example, 
systemic inflammation may trigger a coagulopathy [disseminated intravascular coagulation 
(DIC)] that is characterized by enhanced systemic thrombin generation (Levi and Ten Cate 
1999).  Thrombin can then propagate a vicious cycle by amplifying inflammation through 
various mechanisms (Borissoff, Spronk et al. 2009).  Although anticoagulant therapy is a 
10 
 
tempting strategy for limiting thrombin generation and breaking this vicious cycle, the 
bleeding risk of currently available anticoagulants outweighs any potential benefit during 
sepsis.  Individuals with sepsis therefore represent an additional patient population that may 
benefit from treatment with anticoagulant therapies that do not compromise normal 
hemostasis. 
 
The Plasma Contact System 
 FXI is traditionally considered to be a component of the contact activation pathway, 
or contact system (Figure 2).  The contact system consists of FXII, PK, FXI, and the 
cofactor HK.  Contact activation is initiated when FXII binds to negatively-charged surfaces.  
This binding causes a conformational change in zymogen FXII, resulting in the generation of 
a small amount of FXIIa.  FXIIa then cleaves PK to generate α-kal, which then reciprocally 
cleaves FXII to generate more FXIIa (Bjorkqvist, Nickel et al. 2014).  In addition to its role 
in FXII activation, α-kal also cleaves HK to liberate BK, a pro-inflammatory peptide that 
stimulates prostaglandin and nitric oxide (NO) production, resulting in fever, pain, and tissue 
swelling (Hall 1992).   
Contact activation was initially assumed to be important for coagulation because of 
the observation that blood clots rapidly when exposed to negatively charged (anionic) 
artificial surfaces such as glass or kaolin.  However, current discussions exclude all but one 
contact factor, FXI, when describing hemostasis.  Although the clinical data do not support a 
role for contact activation in hemostasis, there is evidence that contact activation contributes 
to clinically relevant inflammation. For example, hereditary angioedema (HAE), is a rare, 
life-threatening disorder that is characterized by acute episodes of tissue swelling, 
particularly in the skin, gastrointestinal mucosa, and oropharynx (Bjorkqvist, Nickel et al. 
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2014).  HAE results from a functional or quantitative deficiency of C1-inhibitor (C1INH), a 
serine protease inhibitor.  A consistent clinical finding in HAE patients is the presence of 
high levels of BK.  Because C1INH regulates the contact factors FXIIa and α-kal (Gailani 
2010), BK release during HAE episodes is consistent with unchecked contact activation.  
Patients with HAE do not appear to have an increased risk of thrombosis (Bjorkqvist, Nickel 
et al. 2014), suggesting, consistent with the current model described in Figure 3, that contact 
activation does not contribute to coagulation in this setting.     
Contact activation is likely to be an important host defense mechanism against 
microorganisms.   Similar to components of innate immunity, such as the complement 
system, the contact factors can assemble and become activated on the surfaces of bacteria, 
including the human pathogens Streptococcus pyogenes, Staphylococcus aureus, 
Escherichia coli, and Salmonella (Mattsson, Herwald et al. 2001, Herwald, Morgelin et al. 
2003, Frick, Akesson et al. 2006).  Contact activation is triggered through recognition of 
molecular patterns on bacterial surfaces in a manner that is strikingly similar to that observed 
with the complement system (Frick, Bjorck et al. 2007).  Furthermore, consistent with in 
vitro observations of contact activation on negatively-charged surfaces, bacteria and 
damaged cells provide a ready supply of polyanions in the form of phosphate polymers 
[polyphosphate (polyP)], DNA, and RNA (Gailani, Bane et al. 2015).   In addition to 
enhancing the innate immune response to microorganisms through BK release, contact 
activation-induced HK cleavage also generates antimicrobial peptides that directly target 
bacterial pathogens (Frick, Akesson et al. 2006).  The importance of contact activation 
during infection was displayed in a mouse model of S. pyogenes infection using a synthetic 
peptide (H-D-Pro-Phe-Arg-CMK) that specifically inhibits FXIIa and α-kal.  Inhibitor-
treated mice experienced increased bacterial dissemination, suggesting that a functional 
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contact system is instrumental in the host response to bacterial infection (Frick, Akesson et 
al. 2006).  The contact system, like the coagulation system, can also be harmful if activated 
inappropriately.  Because bacteria and damaged cells can trigger contact activation, it stands 
to reason that bacterial infection and cellular injury above a certain threshold may activate 
the contact system to a level that is detrimental to the host.  This is especially true in cases 
where bacteria disseminate and reach the bloodstream (bacteremia), allowing products of 
contact activation to reach the systemic circulation.  BK is a potent vasodilator that may 
cause severe hypotension during sepsis.  Septic patients with low blood pressure display a 
higher level of contact activation than septic patients with normal blood pressure (Mason, 
Kleeberg et al. 1970), while contact system inhibition corrects hypotension in animal models 
of lethal bacteremia (Pixley, De La Cadena et al. 1993).   
While in vitro studies suggest an important role for contact activation in host 
defense, the in vivo significance of this process remains uncertain (Gailani 2010).  Many 
studies have investigated possible mechanisms for FXII activation on a surface. A notable 
finding is that FXIa was shown to activate FXII in plasma and purified systems (Griffin 
1978, Matafonov, Sarilla et al. 2011).  This is perhaps not surprising, given that (a) FXI is 
structurally similar to PK, the zymogen for a protease (α-kal) that activates FXII, and (b) 
FXI and PK arose from a common gene during the course of vertebrate evolution (Ponczek, 
Gailani et al. 2008) and may therefore display similar features.   This raises the possibility 
that FXIa is an effector, rather than simply a product, of contact activation, and that FXI 
links and influences two complex systems: one for thrombin generation, and the other for 
inflammation.   
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CHAPTER III 
 
INTRODUCTION TO FACTOR XI  
 
Factor XI Structure and Function 
FXI, the zymogen of the trypsin-like protease FXIa, is a 160kd protein that is made 
primarily in the liver.  The protein circulates in a complex with the glycoprotein HK at a 
plasma concentration of approximately 30 nM (range of 15-45 nM) (Smith and Gailani 
2008).  FXI is the most recent member of the plasma coagulation system, having arisen from 
a duplication of the gene for the protease zymogen PK (Ponczek, Gailani et al. 2008, Bane 
and Gailani D. 2014).  In humans, FXI has a plasma half-life of approximately 48 hours 
(range of 45-52 hours).  Unlike the vitamin K [“Koagulations-Vitamin”(Kresage N 2005)] 
dependent coagulation proteins (prothrombin, FVII, FIX, and FX), FXI lacks a calcium-
binding γ-carboxyglutamic acid (Gla) domain (Gailani and Smith 2009).  Consequently, FXI 
synthesis does not require vitamin K, and treatment with vitamin K antagonists such as 
warfarin does not affect plasma FXI levels.  Each FXI molecule circulates as a dimer of two 
identical 80kd subunits, which is a unique feature among the coagulation proteins.  The 
functional significance of the dimeric structure is unclear, but may be related to activation of 
zymogen FXI by FXIIa (Geng, Verhamme et al. 2013), or to an interaction between platelets 
and FXI during hemostasis (Gailani and Smith 2009).  Each 607-amino acid FXI subunit 
contains an N-terminal heavy chain consisting of four 90 to 91 amino acid repeats termed 
“apple” domains (numbered A1-A4), and a C-terminal trypsin-like catalytic domain (Figure 
5A) (Emsley, McEwan et al. 2010).  An inter-chain disulfide bond at Cys321 in the A4 
domain (Figures 5A & 5B) links each subunit within the dimer.  The apple domains form a 
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disc-like structure that serves as a platform for binding of FXI to other molecules (Figure 
5C) (Bane and Gailani D. 2014).  For example, HK binds to the FXI monomer within a 
groove formed by A1, A2, and A4 on the side of the platform opposite the catalytic domain, 
while the FXIa substrate FIX binds to the A3 domain (Emsley, McEwan et al. 2010, Bane 
and Gailani 2014).  FXI activation occurs through cleavage of the peptide bond between the 
Arg369 and Ile370 residues, which are located between the A4 and catalytic domains (indicated 
by the black arrowhead on Figure 5A) of each FXI subunit (Gailani and Smith 2009).  The 
proteases thrombin, FXIIa, and FXIa (autoactivation) convert FXI to FXIa in vitro. The 
Figure 5.  Factor XI structure.  (A) Diagram indicating the domain organization of a factor XI 
(FXI) subunit. Each circle represents one amino acid. Cysteine residues that are associated with 
disulfide bonds are shown in black.  FXI is activated through the cleavage of the peptide bond 
(indicated by the black arrowhead) between Arg369 and Ile370. The amino acids of the catalytic triad 
(described in text) are shown in red. A disulfide bond between Cys321 residues on the A4 domains link 
FXI subunits to form (B) a FXI dimer.  (C) The four “apple” domains form a platform upon which the 
catalytic domain rests.   Panels B and C are models based on the crystal structure of FXI.      
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process involves an intermediate, ½-FXIa (only one of the two monomers is activated) that 
may be a major form of activated FXI (Emsley, McEwan et al. 2010).  FXI activation 
induces a conformational change that facilitates FXIa activation of substrate FIX by 
exposing a binding site for FIX on the A3 domain of FXIa (Gailani and Smith 2009).  
Proteolysis of FXIa substrates is mediated by a “catalytic triad” (indicated by the solid red 
circles in Figure 5A) of serine (Ser557), aspartic acid (Asp462), and histidine (His413).  As 
discussed in chapter I, FXIa does not appear to be instrumental in initiating thrombin 
generation.  Rather, it supports the formation of additional thrombin to bolster existing fibrin 
clots that are constantly subjected to numerous endogenous anticoagulant and fibrinolytic 
processes. The bleeding pattern of FXI deficient patients (described below) supports this 
interpretation of FXI’s role in coagulation. 
 
Factor XI Deficiency in Humans and Domestic Animals 
 This dissertation describes studies that compared mice with normal levels of FXI 
(FXI+/+ mice) to those that possessed approximately 50% and 0% of normal levels (FXI+/- 
and FXI-/- mice, respectively) of this protein.  As will be described later in this chapter, FXI 
deficiency is not associated with abnormal hemostasis in laboratory mice.  This section is 
included to briefly summarize the clinical presentation of FXI deficiency in humans (and 
domestic animals) so that the reader is more equipped to relate FXI deficiency in humans to 
FXI deficiency in laboratory mice.   
Although rare in the general population [approximately 1 in 1 million (Asakai, 
Chung et al. 1991)], severe (FXI activity <20% of normal) FXI deficiency is common (1 in 
450) in people of Ashkenazi Jewish descent (Seligsohn 2009).  The true incidence of FXI 
deficiency may be higher, as some patients may not experience bleeding that is of sufficient 
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intensity to require medical attention.  The disorder may remain undiscovered until a 
prolonged aPTT is revealed during routine pre-surgical screening.  In contrast to the X-
linked hemophilias, people with FXI deficiency do not, with the exception of menorrhagia 
(Seligsohn 2009), bleed spontaneously.  For example, hemarthrosis, a hallmark of the 
classical hemophilias, rarely occurs in FXI-deficient patients (Bolton-Maggs 2009).  
Significant hemorrhage, if observed, is usually related to trauma or surgery, particularly in 
tissues where fibrinolysis is most active, such as the oropharynx or genitourinary tract.  For 
instance, approximately 20% of women with FXI deficiency experience excessive bleeding 
related to childbirth (Seligsohn 2009, Santoro, Prejano et al. 2011).  It is postulated that FXIa 
is more important for hemostasis after trauma to these tissues, both for sustaining thrombin 
generation and for providing resistance to fibrinolysis by promoting activation of thrombin 
activatable fibrinolysis inhibitor (Von dem Borne, Bajzar et al. 1997, Bolton-Maggs 2009, 
Bane and Gailani D. 2014).  Bleeding in FXI-deficient patients may occur immediately after 
injury, or may be delayed for several hours (Seligsohn 2009).  Interestingly, there is a poor 
correlation between FXI levels and bleeding tendency.  Some individuals with severe FXI 
deficiency do not bleed at all after trauma (Rapaport, Proctor et al. 1961), while others may 
experience bleeding that varies over time, even after re-exposure to a similar type of injury 
(Asakai, Chung et al. 1991, Bolton-Maggs, Patterson et al. 1995).  The complex clinical 
presentation of FXI deficiency, combined with the potentially serious side effects of FXI 
replacement therapy, provide a difficult challenge to clinicians who manage these patients 
(Bolton-Maggs 2009). 
Congenital FXI deficiency has also been reported in several species of domestic 
animals, where multiple modes of inheritance are described (Marron, Robinson et al. 2004, 
Ohba, Takasu et al. 2008).  The disorder is most widely reported in cattle (Marron, Robinson 
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et al. 2004, Ohba, Takasu et al. 2008), but has also been described in dogs (Knowler, Giger 
et al. 1994) and in a domestic cat (Troxel, Brooks et al. 2002). Some reports describe injury-
related bleeding in FXI-deficient animals (Knowler, Giger et al. 1994, Troxel, Brooks et al. 
2002, Marron, Robinson et al. 2004), while others indicate no apparent bleeding phenotype 
(Ohba, Takasu et al. 2008).   
 
Factor XI and Thrombosis 
In healthy individuals, the mechanisms that promote coagulation are balanced by 
numerous anticoagulant mechanisms that localize clots to the area of tissue injury, where 
they are eventually broken down through fibrinolysis.  A disruption to the procoagulant-
anticoagulant balance may result in excessive bleeding (hemorrhage) or pathologic clot 
formation within blood vessels (thrombosis).  The pathophysiology of thrombosis is 
complex, but has been attributed to increased thrombin generation and/or decreases in 
intrinsic fibrinolytic mechanisms.  In keeping with this hypothesis, most antithrombotic 
therapies are directed at minimizing thrombin generation through inhibition of proteins that 
are vital for normal coagulation.  Such therapies are very effective at preventing thrombosis, 
but, predictably, carry a significant bleeding risk.  This fact is perhaps most vividly 
illustrated by the anticoagulant drug warfarin, a vitamin K-antagonist that is the drug of 
choice for treatment of venous thrombosis and prevention of stroke in patients with non-
valvular atrial fibrillation.  This anticoagulant has been in use since the early 1950’s, but was 
first registered as a rodenticide in 1948 (van Montfoort and Meijers 2013).  Interestingly, 
warfarin is a synthetic analogue of dicoumarol, a compound within spoiled sweet clover that 
was found to be the causative agent of an outbreak of hemorrhagic cattle disease in the 
1920’s (Kresage N 2005). 
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Consistent with traditional reasoning, proteins that are not vital for normal 
hemostasis would be predicted to play a proportionally smaller role in thrombosis.  In the 
case of FXI, studies in humans have challenged this reasoning.  In the Leiden Thrombophilia 
study, patients with plasma FXI levels in the top 10% of the normal distribution were nearly 
twice as likely to develop venous thromboembolism compared to the rest of the study 
population (Meijers, Tekelenburg et al. 2000).  In the same study, men with higher levels of 
FXI were at a 2-fold greater risk for myocardial infarction.  Another study showed a 
correlation between elevated FXI levels and stroke (Yang, Flanders et al. 2006).   
Conversely, population studies of individuals with severe FXI deficiency reveal a lower risk 
for stroke and deep-vein thrombosis (Salomon, Steinberg et al. 2008, Salomon, Steinberg et 
al. 2011).  Severe FXI deficiency has not been shown to be protective against myocardial 
infarction (Salomon, Steinberg et al. 2003), indicating that FXI deficiency may not 
uniformly influence thrombus formation in all tissues.  
 
Factor XI in Animal Models of Thrombosis 
 The observation that humans with FXI deficiency appear to be protected against 
certain thrombotic events has important therapeutic implications, and has supported an 
ongoing interest in research that investigates the role of FXI in experimental thrombosis.  A 
mouse model of FXI deficiency was developed on the C57Bl/6 background by Gailani, et 
al., using homologous recombination in embryonic stem cells.  The mice are fertile, and 
offspring from heterozygous matings follow the expected Mendelian ratio of approximately 
25% wild type (WT), 50% heterozygous null, 25% homozygous null, indicating that partial 
or complete FXI deficiency is not embryonic lethal (Gailani, Lasky et al. 1997).  The aPTT 
in plasma from FXI-deficient (FXI-/-) mice is prolonged compared to WT mice, while 
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clotting times in plasma from mice that are homozygous for the FXI null allele (FXI+/-) are 
intermediate between FXI-/- and WT (FXI+/+) mice.  Under normal conditions, these mice 
have no discernable phenotype and do not bleed excessively when subjected to amputation 
of the tail tip or other invasive procedures (Gailani, Lasky et al. 1997, Renne, Oschatz et al. 
2009). This is in contrast, for example, to FIX-deficient mice, which experience injury-
related (tail transection) hemorrhage that is comparable to animals given high doses of the 
anticoagulant heparin (Wang, Cheng et al. 2005).   
Despite the lack of a bleeding disorder, FXI-/- mice are remarkably resistant to 
experimentally-induced arterial and venous thrombosis (Bane and Gailani 2014).  In an 
important proof of concept study, Rosen, et al. discovered that, in contrast to WT mice, FXI -
/- mice failed to form occlusive thrombi after application of a 20% solution of ferric chloride 
(FeCl3) to the external surface of the carotid artery (Rosen, Gailani et al. 2002).  The ability 
of FXI-/- mice to generate thrombi in response to FeCl3 was restored after infusion of human 
FXI.  Wang and colleagues (Wang, Cheng et al. 2005) used a modified version of this model 
to show that FXI-/- mice were protected from arterial thrombosis to a degree that was 
comparable to FIX deficiency.  Importantly, the Wang study also reported that FXI 
deficiency was superior to aspirin therapy, and conferred a level of thrombosis resistance 
that was similar to treatment with doses of heparin that was well above the therapeutic range.  
Further work has confirmed that FXI is also instrumental in formation of venous thrombi 
(Wang, Smith et al. 2006), and that it contributes to experimental thrombus formation in 
numerous species, including rabbits and baboons (Minnema, Friederich et al. 1998, Gruber 
and Hanson 2003, Yamashita, Nishihira et al. 2006, Tucker, Marzec et al. 2009). 
Interestingly, the animal data also implicate FXII in thrombosis.  For instance, WT mice that 
received a monoclonal antibody that blocks activation of FXI by FXIIa (but not thrombin or 
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FXIa) displayed a resistance to FeCl3 thrombosis that was similar to FXI-deficient mice 
(Cheng, Tucker et al. 2010).  These findings raise the profile of the contact system in 
thrombosis, and support the proposition that thrombus-generating mechanisms may be 
different from hemostatic mechanisms in some instances.  Additional animal models, 
described in the following chapter, indicate that FXI and the contact system also participate 
in inflammation-induced pathology. 
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CHAPTER IV 
 
FACTOR XI AND THE CONTACT SYSTEM IN SEPSIS 
 
Introduction 
As discussed in Chapter II, numerous lines of evidence point to cross-talk between 
coagulation and inflammation.  This chapter describes how both systems are triggered after 
infection, and provides examples of how coagulation and inflammation are intricately linked 
during sepsis.  It is intended to provide a framework to help explain how FXI may contribute 
to morbidity and mortality during sepsis, thus setting the stage for a more complete 
understanding of the data reported in the next chapter.   
An inflammatory syndrome known as sepsis is almost always accompanied by some 
degree of activation of coagulation (Levi 2010, Stearns-Kurosawa, Osuchowski et al. 2011).  
An extreme example of this relationship is DIC, a complication of sepsis that is associated 
with higher mortality (Hook and Abrams 2012).  Contact activation is another complication 
of sepsis.  Septic patients undergo systemic contact activation, as evidenced by consumption 
of contact factors and release of BK (Saugstad, Buo et al. 1992, Mattsson, Herwald et al. 
2001).  Notably, low levels of contact factors are associated with death among patients with 
sepsis (Oehmcke and Herwald 2010), suggesting that contact activation contributes to 
mortality.  The contact activation and coagulation systems contribute to the pathology of 
sepsis through distinct mechanisms.  Although it is extremely difficult to determine the 
precise mechanism of mortality during sepsis, inflammation and contact activation appear to 
figure more prominently than a coagulopathy in the mortality of sepsis in some animal 
models (Pixley, De La Cadena et al. 1993, Jansen, Pixley et al. 1996, Ganopolsky and 
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Castellino 2004, Corral, Yelamos et al. 2005, Iwaki, Cruz-Topete et al. 2008).  FXI, which 
may participate in both coagulation and inflammation, may primarily influence mortality in 
some animal sepsis models through a pro-inflammatory effect.   
 
Overview of Sepsis 
 Sepsis is defined as a systemic inflammatory response to infection (Bone, Balk et al. 
1992).  Clinically, the disorder is the result of a bacterial (gram-positive, gram-negative, or 
mixed) or fungal infection that originates primarily within the lungs, peritoneum, or urinary 
tract (Angus and van der Poll 2013).  Sepsis is diagnosed when there is evidence of a 
systemic inflammatory response syndrome (SIRS) in the face of a confirmed or suspected 
infection (Bone, Balk et al. 1992). Criteria for the diagnosis of SIRS include an elevated 
heart rate, increased respiratory rate, and body temperature and white blood cell counts that 
are either above or below the normal range (Stearns-Kurosawa, Osuchowski et al. 2011).  
Sepsis may progress to severe sepsis, which is defined as SIRS complicated by organ 
dysfunction, and finally to septic shock, which is noted by the development of persistent 
hypotension in addition to the features described for less severe sepsis (Levy, Fink et al. 
2003).  Mortality from sepsis is thought to be a result of either an exaggerated inflammatory 
response, which typically occurs early in the course of the disease, or to prolonged 
immunosuppression, where patients succumb to secondary bacterial infections (Rittirsch, 
Flierl et al. 2008, Stearns-Kurosawa, Osuchowski et al. 2011). Additional complications, 
such as systemic activation of the coagulation and complement systems, may also contribute 
to mortality, particularly in the later stages of sepsis (Russell 2006, Rittirsch, Flierl et al. 
2008, Amara, Flierl et al. 2010). Following is a discussion of the acute inflammatory 
response during the initial stages of sepsis, which is of relevance to this research project. 
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The Inflammatory Response to Infection 
 Inflammation is a feature of innate immunity, which is a nonspecific host response 
to infection and tissue injury.  At its core, acute inflammation is a process of transporting 
cellular and soluble inflammatory factors from the bloodstream to damaged tissues.  This 
occurs through a standard sequence of events:  A local increase in blood flow is followed by 
increased vascular permeability, which facilitates entry of protein-rich edema fluid and 
leukocytes into extravascular sites of injury (Slauson and Cooper 1990).  Edema fluid 
contains nutrients and beneficial proteins, such as coagulation factors and complement 
components, while leukocytes, predominantly neutrophils, augment the local response of 
resident macrophages to engulf, kill, and remove invading pathogens.  The process is 
orchestrated by several types of inflammatory mediators, including cytokines, chemokines, 
and numerous vasoactive molecules.  These mediators are protective when resolving 
infections that are contained locally.  However, they contribute to sepsis morbidity and 
mortality when infections become more widespread.   
   Inflammation is triggered during infections when pathogens and damaged host 
cells express molecules called pathogen-associated molecular patterns (PAMPs) and 
damage- associated molecular patterns (DAMPs), respectively.  These molecules are 
recognized by pattern recognition receptors (PRRs) on resident “sentinel” cells, such as 
macrophages and dendritic cells (Rittirsch, Flierl et al. 2008, Tizard 2008, Angus and van 
der Poll 2013). The classical PAMPs are lipopolysaccharide (LPS) and peptidoglycan within 
the cell walls of gram-negative and gram-positive bacteria, respectively, but PAMPs are also 
expressed by yeasts and viruses (Tizard 2008).  DAMPs, also called alarmins, include high 
mobility group box protein-1 (Tizard 2008), and extracellular DNA, RNA, and histones 
(Chan, Roth et al. 2012).  Toll-like receptors (TLRs) are the most prominent class of PRRs 
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(Tizard 2008).  PAMP/DAMP recognition by PRRs results in the activation of receptor 
complexes on sentinel cells.  This triggers intracellular signaling pathways, resulting in the 
activation of transcription factors, such as NF-κB.  NF-κB and related proteins then regulate 
transcription of the cytokines, chemokines, and vasoactive molecules that contribute to acute 
inflammation.  
 Cytokines are polypeptides that mediate cellular interactions (Tizard 2008).  They 
exert a variety of effects, including activation of immune cells, induction of fever, and 
initiation of the acute phase response.  The major cytokines of acute inflammation are tumor 
necrosis factor α (TNFα), interleukin-1 (IL-1) and interleukin-6 (IL-6).  TNFα and IL-1 have 
nearly identical effects (Sherwood and Toliver-Kinsky 2004) and play a central role in the 
vascular changes that exemplify the acute inflammatory response (Tizard 2008).  IL-6 is a 
major mediator of the acute phase response of the liver (Sherwood and Toliver-Kinsky 2004, 
Tizard 2008), and also stimulates production of additional cytokines, including the anti-
inflammatory cytokine IL-10 (Tizard 2008).  Chemokines are a subset of cytokines that 
regulate the emigration of leukocytes from the bloodstream to the tissues (Tizard 2008).  
Among these are macrophage inflammatory protein-2 (MIP-2) and keratinocyte 
chemoattractant (KC), which attract neutrophils, and monocyte chemotactic protein-1 (MCP-
1), which exerts chemotactic activity on monocytes. 
 Vasodilation is a critical step in acute inflammation.  It facilitates the opening of 
gaps between adjacent vascular endothelial cells to allow passage of edema fluid and 
leukocytes from the intravascular to the extravascular space (Slauson and Cooper 1990, 
Sherwood and Toliver-Kinsky 2004).  Vasoactive molecules, NO, BK, histamine, and 
vasoactive lipids, such as phospholipase, mediate this process (Sherwood and Toliver-
Kinsky 2004, Tizard 2008).  NO is the most important contributor to vasodilation during 
31 
 
sepsis (Vallance and Chan 2001, Sherwood and Toliver-Kinsky 2004).  It is derived from the 
amino acid L-arginine by the enzyme nitric oxide synthase, and acts through cyclic 
guanosine monophosphate-dependent mechanisms to cause vascular smooth muscle 
relaxation.  There are three forms of NOS: endothelial, neuronal, and inducible (Vallance 
and Chan 2001).  The inducible form is released by numerous cell types, primarily 
endothelial cells and macrophages (Moncada, Palmer et al. 1991)  in response to 
inflammatory cytokines and BK (Vallance and Chan 2001, Zhao, Qiu et al. 2001).  In 
addition to its role in vasodilation, NO is also thought to enhance the microbial killing 
efficiency of macrophages (Moncada, Palmer et al. 1991). 
 Severe bacterial infection and/or massive trauma lead to excessive, systemic release 
of the inflammatory mediators described above.  If left unchecked, this systemic 
inflammatory response ultimately results in septic shock, which is characterized by 
irreversible hypotension, organ injury, and death. The coagulation and contact systems 
(described below) are also excessively activated during sepsis. Dysregulation of each 
pathway presents unique challenges that may compromise the host’s ability to survive.  
 
Disseminated Intravascular Coagulation  
 DIC is a dysregulated coagulation response that accompanies a number of primary 
conditions, including sepsis, neoplasia, and trauma (Levi, de Jonge et al. 1999).  The 
syndrome is characterized by intravascular activation of the coagulation system, with 
simultaneous down-regulation of intrinsic anticoagulant and fibrinolytic mechanisms 
(Russell 2006, Hook and Abrams 2012). This condition tips the coagulant-anticoagulant 
balance in favor of coagulation, resulting in ischemic organ damage secondary to widespread 
microvascular thrombosis.  Eventually, DIC causes depletion of platelets and plasma 
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coagulation proteins, resulting in diffuse hemorrhage.  The impact of DIC during sepsis 
depends on several factors, including the intensity of the coagulopathy and any existing 
disease process that may complicate the management of septic patients.  Although 
individuals that develop DIC subsequent to sepsis or severe trauma are twice as likely to die, 
it is unclear if DIC is a definitive mechanism of mortality, or simply an indicator of disease 
severity, in such patients (Levi, de Jonge et al. 1999).   
The coagulation system is activated during sepsis in a number of ways.  Gram-
negative infections trigger coagulation when the LPS component of these organisms 
associates with extracellular LPS-binding protein. This initiates toll-like receptor 4 (TLR4)-
mediated intracellular signaling cascades, resulting in TF expression by circulating 
mononuclear cells (Guha, O'Connell et al. 2001).  Sepsis-induced TF expression is also 
mediated by pro-inflammatory cytokines, particularly IL-6 (Levi 2010).  The consequence of 
inflammation-induced TF expression is the intravascular formation of thrombin, the central 
enzyme in coagulation.  In addition to driving DIC, thrombin also perpetuates the 
inflammation-coagulation cycle by stimulating cytokine production in mononuclear cells 
through protease activated receptor (PAR) cleavage (Borissoff, Spronk et al. 2009).  
Gram-negative sepsis is the best understood cause of DIC (Hook and Abrams 2012), 
and most animal models of DIC employ LPS as the inciting agent (Berthelsen, Kristensen et 
al. 2011).  The role of gram-positive organisms in coagulation is less clear, but is probably 
also related to toll receptor signaling upon recognition of gram-positive associated 
peptidoglycans by TLR2 (Russell 2006, Hook and Abrams 2012).  Patel and co-workers 
used a “two hit” model to explore the influence of gram-negative (LPS) and polymicrobial 
(CLP) sepsis on TLR-mediated thrombosis.  In this study, groups of mice were given IP 
injections of LPS or saline, or were subjected to CLP or sham surgery.  Four to six hours 
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later, a light-dye laser injury was applied to a section of the cremaster vasculature of each 
(living) animal.  Time to thrombosis at this discrete site was then evaluated using intravital 
microscopy.  Thrombosis was enhanced (compared to controls) in laser-injured WT animals 
after CLP and LPS infusion.  LPS infusion enhanced thrombosis in TLR2 deficient mice, but 
did not enhance thrombosis in TLR4 deficient mice.  Conversely, CLP enhanced thrombosis 
in TLR4, but not TLR2, deficient mice.  The authors concluded that CLP promoted laser-
induced thrombosis through a mechanism that required TLR2 signaling, while the pro-
thrombotic manifestations of E. coli endotoxemia required TLR4.  This is consistent with 
our understanding of TLR4 and TLR2 signaling in gram-negative and gram-positive sepsis, 
respectively, since LPS is a component of gram-negative bacteria, while bacteria that enter 
the bloodstream of mice during the initial stages of CLP-induced sepsis are reported to be 
predominantly gram-positive (Hyde, Stith et al. 1990).  Apart from the TLR data, the Patel 
study highlighted additional key differences in the coagulation response elicited by LPS and 
CLP.  Notably, the pro-thrombotic phenotype of the CLP-operated mice disappeared when 
the mice were given intravenous fluid replacement with isotonic saline post-operatively, 
while fluid replacement had no effect on thrombosis in LPS-treated mice.  This is telling, 
considering that they also showed that, in contrast to LPS-treated mice, thrombin-
antithrombin (TAT) complex levels did not rise in mice after CLP (Patel, Soubra et al. 
2010).  Antithrombin is the major plasma inhibitor of thrombin (Egberg and Blomback 
2014), and TAT complex levels are a surrogate marker of thrombin levels (Teitel, Bauer et 
al. 1982).  The authors provided several hypotheses that could explain their observations, 
speculating, for example, that fluid replacement improves microvascular hemodynamics, 
leading to enhanced shear-dependent release of the antiplatelet molecules NO and 
prostacyclin (Saba and Saba 2014). While these data indicate sepsis promotes a pro-
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coagulant state in vivo, the influence of the coagulopathy of sepsis on mortality is 
controversial (Stearns-Kurosawa, Osuchowski et al. 2011).  Corral et al (Corral, Yelamos et 
al. 2005) inhibited the nuclear enzyme PARP-1 in mice and observed reduced inflammation 
and improved survival after LPS infusion or CLP.  Notably, they saw comparable evidence 
of DIC in both PARP-1 deficient and WT mice, leading them to conclude that inflammation, 
not DIC, influenced mortality in their studies.   Conversely, Opal and colleagues (Opal, 
Palardy et al. 2001), observed improved survival in recombinant human tissue factor 
pathway inhibitor (rhTFPI)-treated mice after CLP.  Unfortunately, the authors did not 
evaluate DIC in this study, but TFPI inhibits the TF (extrinsic) pathway of coagulation 
(Lwaleed and Bass 2006), which is the central mechanism for intravascular coagulation 
during sepsis (Opal and Esmon 2003).  Accordingly, it is reasonable to assume that rhTFPI 
treatment would reduce DIC if it were present.  Interestingly, rhTFPI anticoagulant treatment 
improved survival when the cecum was punctured with a small-bore needle (defined as 23 
gauge), but not when injury was inflicted with a large bore needle (defined as 21 gauge).  
This suggests that higher levels of injury may trigger or enhance additional pathways, such 
as contact activation, that exacerbate sepsis pathology.  
In theory, anticoagulant therapy is a rational approach for treating sepsis because it 
addresses both the coagulopathy and the inflammatory response of the disorder by inhibiting 
thrombin.  In practice, such therapies have met with disappointing results, probably because 
anticoagulants increase the bleeding risk in septic patients.  This is illustrated by studies that 
describe hemorrhage in fibrinogen-deficient mice infected with the protozoal parasite 
Toxoplasma gondii and the gram-positive bacteria Listeria monocytogenes (Johnson, 
Berggren et al. 2003, Mullarky, Szaba et al. 2005).  Another hypothesis for treatment failures 
is that antithrombotic therapy actually contributes to sepsis pathology by dampening the 
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protective effects of coagulation during infections.  Many authors speculate the coagulation 
system limits infection through various mechanisms, including the formation of a protective 
fibrin barrier around invading microbes (Ahrenholz and Simmons 1980, Echtenacher, Weigl 
et al. 2001) and up-regulation of inflammation (Szaba and Smiley 2002, Flick, Du et al. 
2004, Adams, Schachtrup et al. 2007).  These effects undoubtedly depend on the degree of 
infection, type of organism, and numerous host factors. 
 
The Contact System and Sepsis  
In contrast to DIC, which some consider to be a “bystander” in the pathology of 
sepsis (Stearns-Kurosawa, Osuchowski et al. 2011), vasodilation secondary to excessive NO 
production is the primary feature of septic shock (Vallance and Chan 2001).  The contact 
activation product BK contributes to vasodilation through the canonical pathway by 
stimulating endothelial NO production (Vallance and Chan 2001, Zhao, Qiu et al. 2001).  
BK also activates phospholipase (Sriskandan and Cohen 2000), which stimulates the release 
of prostaglandins and other vasoactive lipids from cell membranes (Tizard 2008).  Despite 
the traditional association between contact activation and coagulation, animal models have 
demonstrated that hypotension, not coagulopathy, is the primary consequence of infection-
induced contact activation.  Furthermore, there is strong evidence that hypotension is the 
mechanism through which the contact system contributes to sepsis mortality.  Using a 
baboon model of lethal Escherichia coli sepsis, Pixley and colleagues (Pixley, De La Cadena 
et al. 1993) found that an anti-FXII monoclonal antibody reduced contact activation and 
hypotension, and prolonged survival.  Importantly, the antibody did not influence the 
development of DIC.  Consistent with the baboon work, Iwaki, et al(Iwaki, Cruz-Topete et 
al. 2008) found that FXII deficiency improved hypotension but not coagulopathy in 
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endotoxemic mice.  A later study showed that anti-FXII antibody treatment lowered IL-6 
levels in septic baboons (Jansen, Pixley et al. 1996), indicating that contact activation also 
influences cytokine release.  The mechanism of contact activation-induced cytokine release 
during sepsis is not known, but may be related to monocyte stimulation by FXIIa and HK 
fragments (Toossi, Sedor et al. 1992, Khan, Bradford et al. 2006).  These animal studies 
provide evidence that the contact system operates independently of the coagulation system in 
some cases of sepsis.  This proposition is supported by a retrospective analysis of 
streptococcal toxic shock syndrome (STSS) in humans, which noted the absence of DIC in 
patients with an “isolated prolongation of aPTT” (prolonged aPTT with normal PT) 
(Sriskandan and Cohen 2000).  Recall that the aPTT evaluates the intrinsic (contact 
activation) pathway, while the PT evaluates the extrinsic (TF) pathway.  If activation of one 
or both pathways in vivo results in consumption (depletion) of the corresponding coagulation 
factors, the ex vivo observation of isolated prolongation of aPTT suggests that contact 
activation predominates in this syndrome.  Apart from reinforcing the role of the contact 
system in sepsis, the animal and STSS studies suggest contact activation-induced 
hypotension has a relatively greater role than coagulopathy in the morbidity and mortality 
that accompanies some infections.   
 
Factor XI in Animal Models of Sepsis 
The in vitro data, discussed in Chapter II, that indicate FXI influences both contact 
activation/inflammation and coagulation are bolstered by recent findings that point to a role 
for this protein in the host response to infection.  In a murine study of peritonitis induced by 
intraperitoneal injection of the gram-positive intracellular bacteria Listeria monocytogenes 
(Luo, Szaba et al. 2012), FXI-/- mice had improved survival (67%  FXI-/- alive at 10 days 
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compared to 30% for WT, p= 0.04) when challenged with a high dose of L. monocytogenes, 
and displayed reduced levels of plasma IL-6 (p=0.03), and hepatic fibrin (p=0.02).  Markers 
of DIC indicated a less intense coagulopathy in FXI-/- mice compared to WT mice (higher 
fibrinogen [p=0.0005], lower TAT levels [p=0.008], and increased platelet numbers 
[p=0.009]).  Dissemination of the organism to liver and spleen was markedly reduced in 
FXI-/- mice (p=0.007 and 0.0006, respectively).  An interesting finding from this study was 
the discovery that hepatic FXI mRNA levels were elevated in WT mice infected with lethal 
doses of L. monocytogenes.  This suggests FXI synthesis is increased in response to infection 
with this organism.  It should be noted that FXI does not appear to contribute to the 
pathophysiology of all types of infection. For example, FXI deficiency was not protective in 
mice infected with the gram-negative bacteria Yersinia enterocolitica (Luo, Szaba et al. 
2011).  Furthermore, FXI-/- mice were not resistant to the detrimental effects of injections of 
Escherichia coli endotoxin (Tucker, Gailani et al. 2008). 
In a study of sepsis accompanying bacterial peritonitis induced by CLP, Tucker and 
co-workers showed that FXI-/- mice had a survival advantage over WT mice (Tucker, Gailani 
et al. 2008).  One week after CLP, 46% of FXI-/- mice were alive, while only 13% of WT 
mice were alive (P=0.0001).  Markers of DIC [platelet counts, fibrinogen levels, TAT 
complex levels] in blood drawn 24 hours after CLP indicated a less severe coagulopathy in 
FXI-/- mice compared to WT mice.  FXI-/- mice also had lower peritoneal leukocyte counts 
24 hours post CLP compared to WT littermates, suggesting that FXI influenced leukocyte 
trafficking.  In contrast to the Listeria study, the authors found no differences in peritoneal or 
blood levels of bacteria between FXI-/- and WT mice, suggesting there are fundamental 
differences in the disease processes that follow Listeria infection and CLP, respectively.   
More recently, Tucker et al tested an anti-FXI antibody that blocks FXI activation by FXIIa 
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(14E11) in vitro in the CLP model (Tucker, Verbout et al. 2012).   Treatment with 14E11 
improved survival by 30% (p=0.001) in WT mice, when administered up to 12 hours after 
CLP.  14E11-treated mice also had significant attenuation of the inflammatory markers 
TNFα and IL-6 in plasma at 12 hours after CLP.  Surprisingly, WT mice given 14E11 after 
CLP had peritoneal leukocyte counts that were comparable to vehicle (PBS) treated animals 
at 24 hours.  This contrasts with the study using FXI-/- mice, where peritoneal leukocyte 
counts were noted to be lower in the knockout animals, and suggests that FXI-associated 
leukocyte migration is not dependent on the contact system.   
The earlier CLP data indicate FXI is associated with enhanced thrombin generation 
and consumption of platelets and fibrinogen during CLP-induced sepsis.  However, this is 
insufficient evidence to conclude that the mice were in fulminant DIC after CLP.  
Hemorrhage and microvascular thrombosis are hallmarks of DIC in laboratory animals 
(Berthelsen, Kristensen et al. 2011), yet histology of tissues taken 24 hours after CLP was 
unremarkable in the study that compared FXI-/- to WT mice.   These histologic findings were 
similar to those of a prior study by Ganopolsky and colleagues (Ganopolsky and Castellino 
2004) that failed to show severe pathology (including evidence for DIC) in mice 24 hours 
after CLP.  Ganopolsky, et al. concluded that severe DIC is not a feature of CLP-induced 
sepsis, and attributed the unremarkable histology to the acute nature of septic shock after 
CLP.  Considering that plasma inflammatory cytokines correlate with death after CLP in 
mice (Remick, Bolgos et al. 2002, Osuchowski, Welch et al. 2006), the finding that plasma 
TNFα and IL-6 was lower in 14E11-treated mice after CLP is perhaps a better explanation 
for the difference in mortality observed between treatment groups in both Tucker studies.   
Taken together, the earlier studies suggest a role for FXI in the host response to CLP 
injury (summarized in Figure 6).  However, our knowledge of the course of this response in 
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Figure 6.  Role of FXI in polymicrobial sepsis.  Coagulation and inflammation are both triggered 
because of the tissue damage and bacterial release that occurs after CLP.  Both systems work 
synergistically and lead to resolution of the infection when contained at the locus of infection (green 
arrow and box).  However, systemic activation of coagulation and inflammation may contribute to 
morbidity through DIC, endothelial damage, and multiple system organ failure (red arrow and box).  
Using FXI deficient mice, we attempted to define the role of FXI in polymicrobial sepsis by 
evaluating the effects of this protein on survival, and on the coagulopathy and inflammatory response 
induced by CLP.  
WT and FXI-/- mice during polymicrobial sepsis over time was limited to a single time point 
(24 hours).  Studies with the 14E11 antibody were informative, but administration of this 
antibody did not result in FXI deficiency, and thus to blockage of all FXI-related activities. 
The goal of my research project was to address important gaps in our current understanding  
of the mechanisms by which FXI contributes to the pathophysiology of sepsis.  Chapter V 
describes the findings of my project. 
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CHAPTER V 
 
FACTOR XI DEFICIENCY ALTERS THE CYTOKINE RESPONSE AND 
ACTIVATION OF CONTACT PROTEASES DURING MURINE 
POLYMICROBIAL SEPSIS 
 
 
Introduction 
Sepsis, a systemic inflammatory response that may develop with severe bacterial, 
fungal, or viral infection (Levy, Fink et al. 2003), is a major cause of mortality (Dellinger, 
Levy et al. 2013).  It is estimated that nearly twenty million cases of sepsis occur each year 
worldwide, with death occurring in more than 25% of those with severe sepsis (Angus, 
Linde-Zwirble et al. 2001). Inflammation and coagulation are key players in the initial host 
response to infection, and while both are beneficial when localized to an injury site, they can 
be destructive when activated systemically. The hyper-inflammatory response during sepsis 
causes tissue damage and organ dysfunction, resulting in morbidity and mortality, while 
perturbations in coagulation (both thrombotic and hemorrhagic) signal a worsening 
prognosis, further complicating the management of septic patients. 
FXIa contributes to thrombin generation through proteolytic activation of several 
plasma coagulation factors, most prominently FIX (Emsley, McEwan et al. 2010, 
Matafonov, Cheng et al. 2013).  While FXIa serves a relatively modest role hemostasis, it 
makes major contributions to pathologic thrombus formation in a variety of animal models 
(Tucker, Marzec et al. 2009, Cheng, Tucker et al. 2010, Yau, Liao et al. 2014), and appears 
to contribute to thromboembolic disease in humans (Meijers, Tekelenburg et al. 2000, 
Doggen, Rosendaal et al. 2006, Suri, Yamagishi et al. 2010).  Previously, we observed that 
complete deficiency of FXI, the zymogen of FXIa, improved survival in a mouse 
polymicrobial sepsis model induced by ligation and puncture of the cecum (CLP) (Tucker, 
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Gailani et al. 2008). There was evidence of a consumptive coagulopathy in WT C57Bl/6 
mice 24 hours post-CLP that was not evident in FXI-deficient mice. Subsequent work 
showed that a monoclonal anti-mouse FXI IgG (14E11) improved survival in WT mice 
subjected to CLP, with blunting of the coagulopathy (Tucker, Verbout et al. 2012). In that 
study, mice treated with 14E11 immediately after CLP had ~50% reductions in the levels of 
the cytokines IL-6 and TNF- 12 hours after CLP, suggesting FXI inhibition produced an 
anti-inflammatory effect in addition to an anti-thrombotic effect. As inflammatory and 
hemodynamic changes characteristic of septic shock become evident within the first few 
hours after CLP in mice (Walley, Lukacs et al. 1996, Ganopolsky and Castellino 2004, 
Murphy, Morgelin et al. 2011), we investigated the importance of FXI to inflammation and 
coagulation early in the course of CLP-induced polymicrobial sepsis.  We observed 
improved survival in FXI-/- mice, and found significant differences in cytokine responses 
between WT and FXI-/- mice as early as four hours post-CLP.  In contrast to our earlier 
work, which employed a less severe level of injury, we did not find histologic or 
hematologic evidence of consumptive coagulopathy.  Interestingly, while there was evidence 
of contact activation in the plasma of WT mice after CLP, the process was blunted in FXI-
deficient mice.  A mechanism that might explain this observation was investigated.   
   
Materials and Methods 
 
Mice 
For CLP survival studies, C57Bl/6 mice heterozygous for a null FXI allele (FXI+/-) 
(Gailani, Lasky et al. 1997) were crossed to generate WT (FXI+/+), heterozygous null (FXI+/-
), and homozygous null (FXI-/-) mice. FXI genotypes for study mice were determined by 
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PCR. Age-matched 3 to 6-month-old littermates were subjected to CLP. For time course 
studies, FXI+/+ and FXI-/- littermates were used. Animals were housed under a 12-hour 
day/night cycle with unrestricted access to food and water. Experiments were approved by 
the Institutional Animal Care and Use Committee at Vanderbilt University. 
 
Cecal Ligation and Puncture (CLP) model of polymicrobial sepsis  
CLP was carried out as described (Tucker, Gailani et al. 2008, Rittirsch, Huber-Lang 
et al. 2009, Tucker, Verbout et al. 2012). Briefly, mice were anesthetized with isoflurane and 
aseptically prepared for surgery.  A 1 cm midline celiotomy was performed, and the cecum 
was exteriorized. The cecum was ligated using 4-0 coated Vicryl™ (Ethicon, Inc., 
Somerville, NJ) either 1 cm from the distal end (low-grade injury) or at the base just distal to 
the ileocecal valve (high-grade injury). Care was taken to avoid mechanical obstruction of 
the bowel.  The cecum was punctured twice using a sterile 21-gauge hypodermic needle, and 
a drop of cecal contents was expressed.  The cecum was returned to the abdominal cavity, 
the abdominal wall was closed with 4-0 Vicryl™, and the skin was closed with wound clips 
(Roboz Surgical, Gaithersburg, MD). Mice received a 1 mL subcutaneous (SC) injection of 
warmed 0.9% NaCl immediately after surgery, and were monitored on a warming pad until 
recovery.  After consultation with a veterinarian, it was decided not to use analgesics 
because they alter the process being studied. After CLP, mice were evaluated every 6 hours, 
and received 1 mL warm 0.9% NaCl SC daily. At each inspection, animals that (1) were 
moribund (no response to stimulation), (2) in respiratory distress, (3) were cool to touch, (4) 
had dusky discoloration of the tail or ears, or (5) had lost >30% body weight were 
euthanized (CO2 inhalation, followed by cervical dislocation). For pilot studies, WT mice 
underwent low-grade CLP.  At 2, 4, 8, 12, and 24 hours after surgery, mice were 
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anesthetized with isoflurane, blood was collected by cardiac puncture, and the animals were 
sacrificed by cervical dislocation while under isoflurane anesthesia.  For later time course 
studies that compared FXI+/+ and FXI-/- littermates, mice underwent high-grade CLP or sham 
(cecum manipulated without ligation or puncture) surgery, and samples were collected at 4, 
8, and 24 hours post-CLP.  No animals met criteria for euthanasia prior to reaching 
designated time points.    
 
Sample collection and cell counts  
Blood was drawn from control and post-surgical animals by cardiac puncture into a 
1/10th volume of 100 mM EDTA.  Complete blood counts were measured using a 
Hemavet® 950 FS analyzer (Drew Scientific, Waterbury, CT).  Blood samples were then 
immediately centrifuged to obtain platelet poor plasma. Plasma was stored at -80°C. 
 
Measurements of plasma proteins  
Plasma cytokine (IL-1β, IL-6, IL-10, TNFα) levels were measured with a multi-plex 
assay on a Luminex 100 system (Luminex Corporation, Austin, TX). Mouse specific ELISA 
kits were used to measure plasma levels of TAT complex, fibrinogen, and serum amyloid P 
(SAP) (Innovative Research, Novi, MI). Changes in plasma FXII, PK and FXI concentration 
were determined by densitometry of western immunoblots. One microliter samples of mouse 
plasma were size fractionated under non-reducing conditions on 10% polyacrylamide-SDS 
gels, and transferred to nitrocellulose paper.  FXII and PK were detected by HRP-conjugated 
goat anti-human FXII and sheep anti-human PK (Affinity Biologicals, Ancaster, Ontario), 
respectively, while FXI was detected with a biotinylated monoclonal antibody to murine FXI 
(14E11) (Cheng, Tucker et al. 2010), followed by streptavidin-HRP. Detection was by 
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chemiluminescence.  Films were evaluated with BioRad Quantity 1 software (BioRad, 
Richmond, CA). Mean signals for samples obtained from mice that did not undergo surgery 
were arbitrarily assigned a value of 100%, and served as a baseline reference for signals at 
various time points 
 
Histology  
Liver, spleen, thymus, kidney, and brain samples were collected from controls and 
from mice sacrificed at 4, 8, and 24 hours post-CLP or sham surgery, fixed in 10% buffered 
neutral formalin for 24 hours, then processed routinely, embedded in paraffin, longitudinally 
sectioned at 4 microns, and stained with hematoxylin-eosin. Light microscopic evaluation 
was performed by an experienced veterinary pathologist. For each sample, at least 20 high-
power fields of view were evaluated for evidence of fibrin formation, platelet clumping, 
inflammation, lymphoid apoptosis, hemorrhage, and necrosis.  Samples were submitted to 
the pathologist with a numeric code to facilitate blinding.  
 
Chromogenic assay for FXII activation 
Human FXII, FXIa, α-kal and HK were purchased from Enzyme Research 
Laboratory (South Bend, IN). Genomic DNA was isolated from human leukocytes, and total 
RNA from mouse liver. Polyphosphate (60-100 phosphate units) was a gift from Thomas 
Renné (Karolinska Institute). Activation of FXII (200 nM) was studied in 20 mM HEPES, 
pH 7.4, 100 mM NaCl, 0.1% PEG-8000, ZnCl2 (10 µM) at 37 ºC. Reactions included DNA 
(5.0 µg/ml), RNA (5.0 µg/ml), polyphosphate (20 µg/ml), HK (20 nM), α-kal (2.0 nM), or 
FXIa (1.0 nM). At various times, 20 µl of reactions were mixed with 10 µl Polybrene (0.4 
mg/ml) and 40 nM of an anti-kallikrein IgG H03 (Kenniston, Faucette et al. 2014) (for 
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reactions with α-kal) or 40 μM aprotinin (for reactions with FXIa). Ten microliters S-2302 (2 
mM in H2O) was added and ΔOD 405 nm was monitored on a microplate reader. Results 
were compared to a standard curve prepared with pure FXIIa. 
 
Polyphosphate-induced FXII activation in mice  
WT C57Bl/6 mice, and C57Bl/6 lacking FXII (Pauer, Renne et al. 2004), PK 
(Stavrou, Fang et al. 2015), or FXI (Gailani, Lasky et al. 1997) underwent general anesthesia 
with sodium pentobarbital. The abdomen was opened, and polyphosphate (60 mg/kg) in 100 
µL of PBS was infused into the inferior vena cava over 30 seconds. Five minutes later, blood 
was collected from the inferior vena cava into 1/10th volumes of 3.2% sodium citrate, and 
plasma was prepared by centrifugation. Mice were sacrificed by cervical dislocation after 
phlebotomy while still under anesthesia. Plasma samples (1 L) were size fractionated under 
non-reducing conditions on 12% polyacrylamide-SDS-gels, transferred to nitrocellulose 
paper, and developed with HRP-conjugated goat anti-human FXII (Affinity Biologicals). 
Detection was by chemiluminescence. 
 
Statistical analysis  
Data were analyzed using GraphPad Prism® 5.0 software (San Diego, CA).  
Survival differences between groups were evaluated by log-rank test. Differences in 
continuous variables (cytokines, plasma proteins, cell counts) were assessed with a non-
parametric Mann-Whitney test. For densitometric measurements of Western blots, the one-
sample t-test was used to differentiate between mean intensity for each group from signal 
intensity at the pre-surgical baseline (assigned a value of 100%). Data are presented as mean 
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± standard error of the mean (SEM).  A p value of < 0.05 was considered significant for all 
analyses. 
 
Results 
 
FXI deficiency confers a survival advantage after high-grade CLP injury  
FXI-/- and FXI+/- mice had significantly better survival than WT mice (p=0.002 and 
0.003, respectively) after CLP using a high-grade injury level (Figure 7A). Here, in contrast 
to our previous work (Tucker, Gailani et al. 2008), study animals of all genotypes were 
littermates, to address a concern that our earlier observations of a survival difference 
between unrelated FXI-/- and WT mice may have been due to differences in gut flora or 
background genetics.  Overall survival at 7 days post-CLP was 3% in WT mice (n=36), 17% 
in FXI+/- mice (n=41), and 30% in FXI-/- mice (n=33). Hazard ratios were 2.4 (95% 
confidence interval 1.4-4.1) for WT compared to FXI-/- mice, and 2.1 (95% confidence 
interval 1.3-3.6) for WT compared to FXI+/- mice.  Median survival times for WT, FXI+/-, 
and FXI-/- mice were 42, 61, and 54 hours, respectively, while median time to death for mice 
dying after CLP was 42, 52, and 44 hours, respectively. Survival curves between FXI-/- and 
FXI+/- mice were not significantly different (p=0.3).  FXI deficiency conferred a survival 
advantage in male (Figure 7B) and female (Figure 7C) mice, with no differences between 
genders.  Due to concerns regarding effects of the female estrus cycle on the CLP model 
(Zellweger, Wichmann et al. 1997), the remainder of the study was performed using male 
mice. 
Survival was similar between genotypes subjected to CLP with a low-grade injury 
(Figure 7D, p=0.3 for WT vs FXI-/-, p=1.0 for WT vs FXI+/-).  In fact, survival was unrelated 
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to injury grade in FXI-/- mice (Figure 7E), while it was influenced by injury grade for FXI+/-   
(Figure 7F) and WT (Figure 7G) mice. Survival rates for WT and FXI+/- mice, which have 
~100% and ~50% of the normal plasma levels of FXI, respectively, were significantly 
different at low- and high-grade injuries (p=0.0002 for WT, p=0.001 for FXI+/-), while there 
Figure 7. Survival after CLP. (A) Survival of WT (----, n=36), FXI+/- (---, n=41), or FXI-/- (, 
n=33) mice after high-grade CLP injury. *p= 0.002 for WT vs FXI-/- and **p= 0.003 for WT vs 
FXI+/- mice.  Survival in FXI-/- mice was higher than FXI+/- mice (30% vs. 17%), but the difference 
was not significantly different (p= 0.3). (B) Survival for male mice in panel A (n=17, 24, and 18 
for WT, FXI+/-, and FXI-/- mice, respectively). Survival was significantly higher (*p= 0.03) in FXI-
/-, but not FXI+/- (p= 0.09) compared to WT littermates. (C) Survival for female mice in panel A 
(n=19, 17, and 15 for WT, FXI+/-, and FXI-/- mice, respectively). Survival was significantly higher 
(*p= 0.04) in FXI-/- and FXI+/- (**p= 0.01) compared to WT littermates. (D) Survival of WT 
(n=17), FXI+/- (n=28), or FXI-/- (n=19) male mice after low-grade CLP injury. No difference in 
survival was noted between genotypes (p=0.4 for WT vs FXI-/-, p=1.0 for WT vs FXI+/-, p=0.5 for 
FXI-/- vs FXI+/-).  (E-G) Survival curves for male mice from panels B and D, comparing high-grade 
injury () to low-grade injury (----) for (E) FXI-/-, (F) FXI+/-, and (G) WT mice. For FXI-/- mice, 
there was no difference in survival after low- or high- grade injury (p= 0.5), while survival was 
significantly different in FXI+/- (p=0.001) and WT (p= 0.0002) mice between the two levels of 
injury. Curves were compared using the log-rank test.   
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was no difference in survival in FXI-/- mice at the two levels of injury. Taken together, these 
data suggest that FXI contributes to mortality during more severe sepsis, that reduction of 
plasma FXI levels to as much as ̴ 50% of normal may be protective, and that differences in 
gut flora do not explain differences in survival. Because the high-grade injury model 
revealed differences in survival between genotypes, we used this model to assess the effects 
of FXI deficiency on inflammation and coagulation in subsequent studies. 
 
FXI contributes to inflammation during the early stages of sepsis  
We measured plasma levels of cytokines in response to CLP or sham injury, 
concentrating on responses within the first 24 hours to avoid losing study subjects, as deaths 
started occurring within 24 hours of high-grade CLP. Studies focused on cytokines that 
increase early in sepsis, as determined in pilot studies using WT C57Bl/6 mice. In our pilot 
studies, CLP resulted in marked elevations of the pro-inflammatory cytokines TNF-α, IL-1β, 
and IL-6, and the anti-inflammatory cytokine IL-10 (Figures 8A and 8B).    For TNF-α, IL-
1β, and IL-6 there was a peak of activity four hours post-CLP, and for IL-10, 2 hrs. post-
CLP.  A biphasic pattern was observed for some cytokine responses, which is consistent 
with reports from previous investigators (Walley, Lukacs et al. 1996, Torres and De Maio 
2005).  By 8 hours, TNF-α and IL-10 levels were decreased from the initial peak, but were 
again increased (compared to 8 hour levels) at 24 hours (Figures 8B and 8A, respectively).  
Notably, sham surgery did not elicit the profound cytokine response that was observed after 
CLP. Figures 8C and 8D compare plasma levels of TNF-α, IL-1β, IL-6, and IL-10 four 
hours after CLP in pilot studies to levels measured at four hours after sham surgery.  The 
plasma level of serum SAP, a major acute phase protein in rodents that is considered 
comparable to C-reactive protein as an indicator of inflammation in humans (Tizard 2008), 
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was significantly elevated by 24 hours in our pilot studies of WT mice undergoing CLP 
(Figure 8E), consistent with an intense inflammatory response.  
  
 
Figure 8. Pilot studies-plasma cytokine and SAP expression after CLP. Plasma levels of (A) IL-6 
() and IL-10 () and (B) IL-1 () and TNFα () at various time points after CLP in WT mice. 
Plasma levels of (C) IL-6 () and IL-10 () and (D) IL-1 () and TNFα () in WT mice 4 hours 
after CLP or sham surgery (sham levels are from a separate study). Note that the IL-6 levels at 4 hr. in 
CLP mice exceeded the upper limit of the assay (20 ng/ml). (E) Plasma levels of serum amyloid P 
(SAP) at various time points after CLP in WT mice. Error bars represent SEM. N=3-4 mice per group. 
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Cytokine data for time course studies comparing FXI+/+ mice with FXI-/- littermates 
are displayed in Figure 9, and are expressed as fold-increase compared to sham surgery to 
illustrate the impact of high-grade CLP over and above anesthesia and celiotomy alone.  
Increases in plasma cytokine levels were significantly greater in FXI+/+ mice than in FXI-/- 
mice 4 hours post-CLP for TNF-α (Figure 9A, p=0.009), IL-1β (Figure 9B, p=0.0009), IL-6 
(Figure 9C, p=0.003), and IL-10 (Figure 9D, p=0.0003).  For TNF-α (Figure 9E) and IL-6 
(Figure 9G) the second increase in cytokine levels was present at 24 hours in both 
genotypes. Indeed, for IL-6, the increases at 8 and 24 hours were significantly greater in 
FXI-/- mice than WT mice (p=0.04). The levels of IL-1β increased more in FXI-/- mice than 
WT mice 8 hours post-CLP (Figure 9F, p=0.08), suggesting a delay in the early increase at 
4 hours observed in WT mice. For IL-10, both early (4 hr.) and late (24 hr.) changes were 
reduced in FXI-/- mice (Figure 9H), but only the early reduction reached significance (4 hrs. 
p=0.0003, 24 hrs. p=0.9) compared to WT mice.  Analysis of absolute cytokine levels 
(Figure 10) revealed that Plasma TNF-α (Figure 10A) and IL-10 (Figure 10D) levels were 
significantly greater in WT mice than in FXI-/- mice 4 hours post-CLP (p= 0.006 and 0.0003, 
respectively), while there was a trend toward higher IL-1β and IL-6 levels four hours post-
CLP in WT animals (p= 0.16 and 0.06, respectively). Later increases out to 24 hours for 
TNF-α, IL-6, and IL-10 were comparable between genotypes. Peak IL-1β levels were similar 
between WT and FXI-/- mice, however, they occurred later (8 hrs.) in FXI-/- mice than in WT 
mice (4 hrs.).  The data demonstrate that absence of FXI alters the normal (WT) cytokine 
response pattern induced by CLP, with prominent blunting of the early response within the 
first few hours after injury.  
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Figure 9. Fold increases in plasma cytokine levels after CLP. Plasma cytokine concentrations 
were measured by multiplex (Luminex 100) assay, and are displayed as fold-increases for 
TNFα, IL-1, IL-6 and IL-10 in WT (black bars) and FXI-/- (white bars) littermates after high-
grade CLP, compared to sham treated animals. Panels A to D are comparisons 4 hr. post-CLP, 
and panels E to H are comparisons 0, 4, 8, and 24 hr. post-CLP. Eight or nine mice were tested 
at each time point for each genotype for CLP, and three mice were used at each time point for 
each genotype for sham surgery. Increases in plasma levels of TNFα, (p=0.009), IL-1, 
(p=0.009), IL-6 (p=0.003) and IL-10 (p=0.0003) were significantly greater in WT mice than in 
FXI-/- mice 4 hr. post-CLP. For IL-6, FXI-/- mice had significantly greater increases in plasma 
levels 8 (**p=0.005) and 24 hr. (**p=0.04) post-CLP than did WT mice. Error bars represent 
SEM. 
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  Figure 10. Absolute increases in plasma cytokine levels after CLP. Shown are plasma 
concentrations of (A) TNFα, (B) IL-1, (C) IL-6 and (D) IL-10 in WT (black bars) and FXI-/- 
(white bars) littermates at various times after high-grade CLP. Eight or nine mice were tested at 
each time point for each genotype for CLP; n=8-9 for non-operated controls. Plasma TNFα (A, 
p=0.006) and IL-10 (C, p=0.0003) levels were significantly greater in WT mice than in FXI-/- mice 
4 hr. post-CLP. Error bars represent SEM. 
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Plasma concentrations of SAP were ~5-fold lower in FXI-/- mice compared to WT 
mice 24 hours post-CLP (Figure 11). In fact, SAP levels in FXI-/- mice undergoing CLP 
were comparable to those observed in mice undergoing sham surgery. This finding suggests 
that the overall effect of FXI deficiency in this model is anti-inflammatory.   
 
Evaluation of evidence for CLP-induced coagulopathy  
Previously, we observed decreased fibrinogen and platelets, and elevated TAT 
complex in blood from WT mice 24 hours after low-grade CLP, consistent with 
disseminated intravascular coagulation (DIC).  In the present study, which utilized high-
grade CLP, we saw little evidence for severe DIC in WT or FXI-/- mice over the 24-hr. 
period post-CLP.  Reductions in platelet counts were present for both genotypes (Figure 
12A, WT baseline 559 ± 37 X 103/mm3, 24 hours post-CLP 339 ± 47 X 103/mm3, p=0.003; 
Figure 11. SAP levels post-CLP. Plasma levels of SAP measured by ELISA in control mice (C, 
n=4) not undergoing surgery, and 24 hr. post-CLP (n=8-9) or sham (Sh n=3) surgery. Black bars are 
results for WT mice and white bars for FXI-/- mice. Error bars represent SEM. 
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FXI-/- baseline 664 ± 34 X 103/mm3, 24 hours post-CLP 362 ± 37 X 103/mm3, p=0.001), 
although the mean platelet counts remained above 300,000 cells/μL in both groups (Figure 
12A). Platelet count reductions were significantly greater with CLP than with sham surgery 
(Figure 12B). For both genotypes, plasma TAT levels did not increase significantly above 
baseline (Figure 12C), and were not different from animals undergoing sham operations 
(Figure 12D). Levels of fibrinogen decreased modestly over the first 4 to 8 hours post-CLP, 
then increased in both genotypes (Figure 12E, WT: baseline 1.7 ± 0.2 mg/mL, 24 hrs. 3.3 ± 
1.0 mg/mL; FXI-/-: baseline 1.7 ± 0.2, 24 hrs. 2.1 ± 0.4). The results at 24 hours for CLP-
treated mice and sham-treatment did not reach statistical significance for either genotype 
(Figure 12F). These results are consistent with work from Patel et al. that showed large 
increases in TAT in C57Bl6 mice after LPS administration, but not after CLP (Patel, Soubra 
et al. 2010). While changes in fibrinogen were not significant for either genotype, there is an 
impression that the level at 24 hrs. was somewhat greater in WT mice than in FXI-/- mice. 
Fibrinogen levels rise with inflammation, and the modest difference could reflect the greater 
inflammatory response induced by CLP in WT mice.  
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Figure 12. Effects of CLP on markers of coagulation. (A, B) Whole blood platelet counts, (C, D) 
plasma thrombin-antithrombin complex (TAT) levels, and (E, F) plasma fibrinogen levels in WT 
(black bars) and FXI-/- (white bars) mice after CLP or sham surgery. Panels A, C and E show values 
various times post-CLP. Panels B, D and F compare values 24 hour post-CLP or sham (Sh) surgery to 
0 hr. controls. CLP induced significant platelet reductions in WT (*p=0.003) and FXI-/- (**p=0.001) 
mice. For panels A to F, error bars represent SEM. 
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At necropsy 24 hours post-CLP, lymphocyte apoptosis, a common finding in murine 
sepsis (Lang and Matute-Bello 2009), was noted in spleen and thymus for both genotypes 
(Figure 13). There was no evidence of hemorrhage. Histologic analysis of multiple organs 
including liver, kidney, brain, spleen, and thymus (Figures 13 and 14) did not reveal 
microvascular thrombus accumulation, which is considered essential for diagnosing DIC in 
laboratory animals (Berthelsen, Kristensen et al. 2011). Cumulatively, these data are 
consistent with published studies indicating that DIC is not a prominent feature of sepsis in 
mice during the first 24 hours after high-grade CLP (Ganopolsky and Castellino 2004, Patel, 
Soubra et al. 2010). 
 
 
 
Figure 13.  Histology of thymus and spleen.  Photomicrographs (400X magnification) of paraffin 
embedded sections of spleen and thymus stained with hematoxylin and eosin before, and 24 hours 
after, CLP in WT and FXI-/- mice. Evidence of lymphocyte apoptosis (indicated by white arrows) 
was present in both organs for mice of both genotypes 24 hrs. post-CLP. 
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62  Figure 14. Histology of liver, brain, and kidney. Photomicrographs (400X magnification) of 
paraffin embedded sections of mouse liver, kidney and brain stained with hematoxylin and eosin 
before, and 24 hours after, CLP in WT and FXI-/- mice. There was no evidence of disseminated 
intravascular coagulation in animals of either genotype following cecal ligation and puncture.  
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Effects of CLP on plasma levels of contact protease zymogens  
During contact activation-initiated coagulation in vitro, the plasma zymogen FXII is 
activated on a surface to generate the protease FXIIa, which cleaves PK and FXI to release 
-kal and FXIa, respectively (Bjorkqvist, Nickel et al. 2014, Schmaier 2014, Wu 2015). 
According to current models of contact activation, α-kal amplifies the process by 
reciprocally activating FXII and also contributes to inflammation by cleaving HK to release 
the pro-inflammatory peptide BK.  FXIa augments thrombin generation by activating FIX, 
but is not considered important for FXII activation.  
During sepsis, blood may be exposed to a variety of substances that induce contact 
activation, including polyphosphate (polyP) released from platelets (Muller, Mutch et al. 
2009) or microorganisms (Herwald, Morgelin et al. 2003, Frick, Bjorck et al. 2007, Yun and 
Morrissey 2009), and extracellular nucleic acids including DNA and RNA from damaged 
tissue and chromatin extruded from activated neutrophils (neutrophil extracellular 
traps)(Esmon 2013, Gould, Lysov et al. 2015). Noting that in vivo activation of contact 
system proteins has been assessed by measuring reductions in plasma levels of their 
respective zymogens (Oschatz, Maas et al. 2011), we measured changes in plasma FXII, PK, 
and FXI levels to assess contact system activation.  In WT mice, FXI decreased by ~50% by 
8 hours after CLP (Figures 15A and 15B), and PK was comparably reduced by 24 hours 
(Figures 15B and 15C). While FXII levels remained similar to baseline in WT mice post-
CLP, we observed a modest increase in plasma FXII levels in FXI-/- mice (Figure 15D).  
FXII levels were also moderately increased in sham-treated animals (not shown), suggesting 
a reaction to surgery. The data, therefore, indicate that there is activation and consumption of 
FXII in WT mice after CLP that was not as prominent in FXI-/- mice.  Interestingly, PK 
levels were not reduced 24 hours post-CLP in FXI-/- mice (Figure 15D). Taken as a whole, 
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the data are consistent with activation of the contact proteases during CLP-induced sepsis in 
WT mice, but suggest that FXI deficiency blunts this process. 
 
Figure 15. The effect of CLP on plasma contact proteases. Plasma FXI, PK and FXII levels at 
various times after high-grade CLP were determined using densitometry of western blots and are 
reported as percent of baseline (0 hr.) control. (A) Plasma FXI levels after CLP in WT mice (B) 
Examples of western blots for FXI and PK for WT mouse plasma at various times after CLP 
(upper panels of each pair) or sham surgery (lower panels of each pair). (C) Plasma PK levels after 
high-grade CLP in WT (black bars) or FXI-/- (white bars) mice. The asterisk above the 24-hr. bar 
for PK in WT animals indicates the value is significantly different than 0 hr. control (p<0.05). (D) 
Plasma FXII levels after high-grade CLP in WT (black bars) or FXI-/- (white bars) mice. In panels 
A, C, and D, each bar represents data for eight mice. For all panels, error bars represent SEM. 
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FXII activation by α-kal and FXIa 
To explore the possibility that FXI may have contributed to contact activation in our 
study, we first evaluated FXII activation by α-kal or FXIa in vitro in the presence of the 
polyanions DNA, RNA, and polyphosphate. FXII was converted to FXIIa at comparable 
relatively low rates by -kal and FXIa in the absence of a polyanion (Figure 16A). The 
FXIa-mediated reaction was enhanced 56-fold by DNA (Figure 16B) and 90-fold by RNA 
(Figure 16C). With -kal, DNA and RNA enhanced FXII activation modestly (2.8 and 5.6-
fold, respectively). In reactions with polyP, contributions of -kal and FXIa to FXII 
activation appeared comparable, but were difficult to assess because FXII autoactivation was 
prominent (Figure 16D). FXI and PK are homologs (Emsley, McEwan et al. 2010), and can 
be difficult to separate chromatographically when purified from plasma. To address the 
concern that FXIa was contaminated with -kal, we ran reactions in the presence of an anti-
kallikrein IgG (H03) that binds to the protease active site (Kenniston, Faucette et al. 2014).  
H03 blocked cleavage of chromogenic substrate S-2302 by α-kal, but not FXIa or FXIIa 
(Figure 17A).  H03 blocked FXII activation by -kal (Figure 17B) but did not affect FXII 
activation by FXIa (Figure 17C), thus illustrating that FXIa can cleave FXII under 
conditions that block the enzymatic activity of α-kal. 
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Figure 16. FXII activation by -kal or FXIa in the presence of polyanions. (A) FXII (200 nM) 
was incubated with vehicle (), 1nM FXIa (), or 2 nM -kal (). (B-D) FXII (200 nM) 
incubated with 5 ug/ml (B) DNA (,), (C) 5 ug/ml RNA (,) or (D) 20 g/ml Poly-P (,), 
in the presence of 1 nM FXIa (,,) or 2 nM -kal (,,). At the indicated times, samples 
were tested for FXIIa activity by chromogenic assay. Error bars are +/ one standard deviation. 
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Figure 17. Effect of anti-kallikrein antibody H03.  (A) FXIIa (100 nM), -kal (5 nM) or FXIa (5 nM) 
were incubated at room temperature for 3 min with 10-fold molar excess of anti-kal antibody (H03) 
respectively or control vehicle (C) in a buffer with 10 M ZnCl2, and residual activity was determined 
by chromogenic substrate. Error bars are +/ one standard deviation. (B) -al (5 nM) and 10 M ZnCl2 
were incubated with the chromogenic substrate S-2302 (200 uM) in the presence of vehicle (), 100 
nM H03 () or 100 nM H03 and 10 ug/ml DNA () and changes in OD 405 nm were monitored. (C) 
FXII (200 nM) and 10 M ZnCl2 were incubated with vehicle (), 5 nM -kal (), 5 nM -kal and 
100 nM H03 (), or 5 nM -kal with 100 nM H03 and 10 ug/ml DNA () in the presence of S-2302 
(200 uM). Changes in OD 405 nm were monitored. (D) FXII (200 nM) and 10 M ZnCl2 were 
incubated with vehicle (), 5 nM FXI (), 5 nM FXI and 10 ug/ml DNA (), or 5 nM FXI and 10 
ug/ml DNA with 100 nM H03 () in the presence of S-2302 (200 uM). Changes in OD 405 nm were 
monitored 
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Three-quarters of PK and nearly all FXI in plasma circulates as a complex with the 
glycoprotein HK (Mandle, Colman et al. 1976, Thompson, Mandle et al. 1977, Thompson, 
Mandle et al. 1979). HK is thought to be required for proper binding of PK and FXI to the 
contact surface during contact activation. Consistent with the importance of HK during 
contact activation on non-biologic surfaces such as kaolin (Meier, Pierce et al. 1977, 
Wiggins, Bouma et al. 1977), HK enhanced FXII activation by -kal with polyP (Figure 
18A), DNA (Figure 18B) or RNA (Figure 18C). In contrast, HK had no appreciable effect 
on FXII activation by FXIa in the presence of polyP (Figure 18D), and a modest inhibitory 
Figure 18. Effect of HK on FXII activation in the presence of polyanions. Plasma FXII (200 nM) 
was incubated with (A-C) 2 nM -kal or (D-F) 1 nM FXIa and (A, D) 20 g/ml poly-P, (B, E) 5 
g/ml DNA or (C, F) 5 g/ml RNA in the absence (,,) or presence (,,) of 20 nM HK. At 
the indicated times, samples were tested for FXIIa activity by chromogenic assay. Error bars are +/ 
one standard deviation. 
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effect with DNA (Figure 18E) or RNA (Figure 18F). These data suggest that -kal (in an 
HK-dependent manner) and FXIa (in an HK-independent manner) can both activate FXII in 
vitro, and support the notion that FXIa may be an activator FXII in vivo. 
 
Effects of polyphosphate infusion on FXII in mice.  
To determine if polyanions induce FXIa-mediated FXII activation in vivo, we 
injected polyphosphate into WT mice and mice lacking PK, FXI, or FXII, and the effect on 
plasma FXII was analyzed by Western blot (Figure 19).  Intravenous infusion of 
polyphosphate induces rapid FXII-dependent thrombosis in mice (Muller, Mutch et al. 
2009), indicating that polyphosphate induces contact activation in this model. In WT mice, 
Figure 19. Polyphosphate-induced changes in FXII in mice. WT C57Bl/6 mice or C57Bl/6 mice 
lacking FXI (XI-/-), PK (PK-/-) or FXII (XII-/-) received a bolus infusion of phosphate buffered saline 
(saline) or PBS containing 60 g of polyphosphate into the inferior vena cava. Five minutes later blood 
was drawn from the inferior vena cava into sodium citrate anticoagulant. Plasma samples were analyzed 
by western blot for FXII under non-reducing conditions. The blot contains samples for two mice of each 
genotype. The position of the FXII zymogen band is indicated on the left (FXII). Free FXIIa would also 
run in this position. The higher molecular mass FXII specific-species likely represent FXIIa in SDS-
stable complexes with plasma serine protease inhibitors (serpins).  
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infusion of polyP, but not saline, caused a modest decrease in intensity of the band 
representing FXII, and produced higher molecular weight species that likely represent FXIIa 
in SDS-stable complexes with serpins such as C1-inhibitor and antithrombin. There were no 
bands on blots with plasma from polyP treated FXII-deficient mice, indicating the high 
molecular mass bands on blots for WT mice are specific FXII/XIIa signals. No changes were 
apparent in the FXII band in PK-deficient mice after polyP infusion, and no higher 
molecular mass species appeared. This is consistent with the impression that PK is required 
for normal FXII turnover in healthy mice (Revenko, Gao et al. 2011). Surprisingly, FXI 
deficiency also affected polyphosphate-induced changes in FXII, although perhaps not quite 
as profoundly as did PK deficiency.  Bands for the higher molecular weight species were 
markedly less intense in blots for FXI-/- mice than for WT mice. These data support the 
hypothesis that -kallikrein and FXIa are required for optimal FXII activation after 
polyphosphate infusion in mice, and are consistent with the notion that FXI deficiency may 
interfere with activation of contact proteases in the CLP model. 
 
Discussion  
The protease FXIa, which plays a relatively modest role in hemostasis, has been 
identified as contributing to pathologic coagulation in humans (Meijers, Tekelenburg et al. 
2000, Doggen, Rosendaal et al. 2006, Suri, Yamagishi et al. 2010, Bane and Gailani 2014, 
Key 2014). Consistent with this, we previously reported evidence for DIC in WT mice after 
CLP but not in similarly treated FXI-/- mice, or WT mice receiving the anti-FXI IgG 14E11 
(Tucker, Gailani et al. 2008, Tucker, Verbout et al. 2012). We concluded that the survival 
advantage after CLP conferred by absence of FXI was primarily due to blunting of sepsis-
induced coagulation. However, WT mice treated with 14E11 also had lower plasma levels of 
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TNFα and IL-6 twelve hours post-CLP than vehicle-treated mice (Tucker, Verbout et al. 
2012), suggesting FXI inhibition affected cytokine responses. The study presented here 
explored the importance of FXI in early cytokine and coagulation responses after CLP.  
The survival data from WT mice show that mortality increased as injury severity 
increased.  This is in keeping with the literature, which indicates that mortality after CLP 
correlates with the proportion of the cecum that is ligated (Rittirsch, Huber-Lang et al. 2009, 
Toscano, Ganea et al. 2011).  In contrast to this paradigm, the data show that FXI deficiency 
confers a survival advantage after high-grade, but not low grade, CLP.  This suggests the 
contribution of FXI is more prominent in severe sepsis.  The findings are consistent with a 
previous observation that FXI-/- mice had better survival when exposed to a dose of Listeria 
monocytogenes that was uniformly lethal in WT mice, but not after inoculation with a lower 
concentration of organisms (Luo, Szaba et al. 2012).  It is unclear why FXI deficiency did 
not reduce mortality with low-grade injury in the current study. In contrast to the earlier 
study, WT and FXI-/- mice were littermates in the work presented here. It is plausible that 
differences in gut flora between separate inbred lines of WT and FXI-/- affected earlier 
results.  In septic patients, death is likely due to a constellation of factors, including 
hypotension, the systemic inflammatory response, DIC, and the specific microorganism 
involved (Russell 2006).  We did not determine causes of death post-CLP, but previous work 
provides some insight.  Death in our study occurred during the “early” or “acute” phase 
(within the first 4 or 5 days) of sepsis (Osuchowski, Welch et al. 2006, Xiao, Siddiqui et al. 
2006). Deaths during this phase correlate with elevations in pro- and anti-inflammatory 
cytokines (Osuchowski, Welch et al. 2006).  The altered cytokine pattern after high-grade 
CLP in FXI-/- mice suggests that a FXI contribution to systemic inflammation figures 
prominently in mortality in WT animals.   
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The difference in levels of the acute phase protein SAP in WT and FXI-/- mice 24 
hours post-CLP suggests that the altered cytokine response in FXI-/- mice was associated 
with a less robust inflammatory response compared to WT mice.  Previous work with mouse 
models indirectly suggested that FXI contributions to inflammation. Mice lacking the key 
coagulation regulatory protease protein C typically die in utero from extensive thrombosis. 
Chan and coworkers (Chan, Ganopolsky et al. 2001) reported that superimposing total FXI 
deficiency on protein C deficiency partially overcomes this phenotype, with some animals 
living to adulthood. Interestingly, despite the well described anti-inflammatory effect of 
protein C, mice lacking both protein C and FXI had similar plasma and tissue TNF and IL-
6 levels to littermates with normal protein C levels.  Kleinschnitz and co-workers 
(Kleinschnitz, Stoll et al. 2006) showed that mice lacking either FXII or FXI display a 
marked reduction in cerebral ischemia-reperfusion injury compared to WT mice after 
temporary occlusion of the middle cerebral artery. The results were attributed to reduced 
fibrin deposition in the null animals, but injury in this model is known to have a significant 
inflammatory component (Carmichael 2005).  The mechanisms by which FXI contributes to 
inflammation in the CLP-model are not clear. In earlier work with a low-grade injury CLP 
model, we noted evidence of DIC in WT mice that was not present in FXI-deficient animals, 
raising the possibility that the pro-inflammatory effects of FXI are related to its well-
characterized role in generating thrombin.  Surprisingly, we did not observe evidence for 
consumptive coagulation during the 24 hours post-CLP in WT or FXI-/- mice; findings that 
are discrepant with our prior experience. Several factors may have contributed to the 
different results. First, CLP, unlike LPS, does not consistently induce DIC in mice 
(Ganopolsky and Castellino 2004, Patel, Soubra et al. 2010). It is also possible that 
differences in gut flora between inbred lines were a factor in our original studies. 
72 
 
Alternatively, our earlier studies used a lower grade injury than was used in the present 
work, and differences in injury level may create models with different features (Rittirsch, 
Huber-Lang et al. 2009). These issues aside, an important point that can be taken from the 
cumulative experience is that FXI deficiency confers a survival advantage after CLP, 
regardless of the presence or absence of DIC. This in turn suggests that the detrimental 
effects of FXI in this model are not primarily tied to consumptive coagulation. 
 Our findings indicate that it is likely that FXI makes thrombin-independent 
contributions to inflammation. For example, while FXIa is classically considered a product 
of contact activation, and not a contributor to the process itself, our results raise the 
possibility that FXIa may contribute to the turnover of the two main zymogens (FXII and 
PK) involved in contact activation.   During contact activation, FXIIa converts PK to -kal, 
which then cleaves HK, liberating the nonapeptide BK, and forming cleaved kininogen 
(HKa) and antimicrobial peptides. BK is a potent vasodilator and inducer of vascular 
permeability (Couture, Blaes et al. 2014, Sharma 2014), and contact activation-induced 
hypotension may be an important contributor to mortality in sepsis. Contact activation is 
probably triggered by traces of FXIIa and/or -kal present in plasma, and are enhanced by 
substances such as the polyanions used in our experiments. HK is an essential co-factor for 
the process, facilitating PK binding to the surface (Meier, Pierce et al. 1977, Wiggins, 
Bouma et al. 1977). Our data indicate FXIa activates FXII in the presence of certain types of 
surfaces in an HK-independent manner. In 1978 Griffin reported that FXIa activates FXII on 
celite (diatomaceous earth), although significantly more slowly than the -kal-mediated 
reaction (Griffin 1978). In our experiments with polyP or nucleic acids, FXIa was a 
significantly better activator of FXII than -kal in the absence of HK, with the difference 
largely disappearing when HK was included in reactions. The reason for this is not certain, 
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but FXI does contain anion-binding sites not found on PK that may allow it to interact 
properly with polyanions in the absence of HK (Geng, Verhamme et al. 2013).   In addition 
to the effects mentioned above, products of contact activation may also contribute to 
increased cytokine levels.  FXIIa (Toossi, Sedor et al. 1992) and peptides derived from HK 
cleavage (Khan, Bradford et al. 2006) can elicit cytokine release in human mononuclear 
cells.   FXIa may indirectly contribute to a cytokine response by affecting cleavage of these 
contact proteins.  
 Targeting thrombin generation with anticoagulants such as heparin appears to be of 
some benefit in patients with severe sepsis (Wang, Chi et al. 2014), probably by limiting 
tissue damage from thrombosis, DIC, and perhaps inflammation. However, such therapy 
increases bleeding in patients who are already coagulopathic, limiting its applicability. The 
anti-inflammatory effects of activated protein C (rhAPC, a.k.a., Xigris®) in sepsis were 
probably partially offset by increased bleeding due to proteolysis of factors Va and VIIIa 
(Warren, Suffredini et al. 2002). Our work suggests that FXI inhibition may provide a 
benefit early in sepsis by altering the inflammatory response. While the CLP-model used in 
the current study did not include a major coagulopathic component, earlier work suggests 
that FXI inhibition may also blunt the DIC that frequently accompanies severe sepsis in 
humans. The importance of FXI to hemostasis in the setting of sepsis in humans remains to 
be established, but based on clinical observations of patients with congenital FXI deficiency, 
FXI inhibition would likely be safer than anticoagulation with heparin.  
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Additional Experiments 
 
Effect of CLP on plasma C5a and chemokine levels.  
The blunted early cytokine response in FXI-/- mice undergoing CLP raises the 
possibility of a suboptimal initial immune response to infection. With this in mind, we 
measured factors known to affect leukocyte migration in response to CLP. C5a is a 
proteolytic fragment of the complement protein C5 that enhances neutrophil migration and 
adherence.  It is also an anaphylatoxin that has been linked to deleterious outcomes in 
experimental sepsis (Ward 2010). As FXIa cleaves C5 to form C5a in vitro (Amara, Flierl et 
al. 2010), we measured plasma C5a levels by ELISA (R & D Systems, Minneapolis, MN) 24 
hours after CLP or sham surgery in WT and FXI-/- mice.  Both types of surgery induced 
comparable elevations of plasma C5a 24 hours post-procedure in WT and FXI-/- mice 
(Figure 20A). Levels of the murine neutrophil chemoattractants KC (Figure 20B) and MIP-
2 (Figure 20C) were elevated in WT and FXI-/- mice within four hours of CLP (Figures 20E 
& 20G), with levels reaching comparable levels by 24 hours. We also measured levels of the 
monocyte chemoattractant protein MCP-1, which is reported to affect leukocyte recruitment 
through a mechanism that is at least partly independent of MIP-2 and KC (Matsukawa, 
Hogaboam et al. 1999). While MCP-1 levels were somewhat lower in FXI-/- mice compared 
to WT animals at 4 and 24 hours after CLP (Figure 20D) the difference was not statistically 
significant.  Cumulatively, the data indicate that processes that stimulate leukocyte migration 
are largely intact in FXI-/- mice, despite the blunted initial cytokine response. 
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Leukocyte migration into the peritoneal cavity 
Since the chemokine response appeared to be intact, we assessed leukocyte 
infiltration into the peritoneum after high-grade CLP (Figure 21).  We noted significant 
increases in total leukocytes in the peritoneal cavity in both WT (baseline 9 ± 0.7 X 103 cells, 
24 hours post-CLP 50 ± 12 X 103, p=0.0007) and FXI-/- (baseline 9 ±1.1 X 103 cells, 24 
hours post-CLP 29 ± 4 X 103 p=0.0002) mice 24 hours post-CLP, (Figure 21A). While the 
increase appeared to be somewhat greater in WT mice (50 ± 12 X 103 for WT vs. 29 ± 4 X 
103 for FXI-/-), the difference was not significant (p=0.4), a trend that was repeated in the 
Figure 20. Complement component C5a and chemokine responses to CLP. For all panels, 
results for WT mice are represented by black bars and for FXI-/- mice by white bars. C5a levels 
were measured by ELISA, while chemokine levels were measured by Luminex technology.  (A) 
Plasma levels of C5a in control mice (C) not undergoing surgery, and 24 hr. post-CLP or sham (Sh) 
surgery. For both genotypes, sham surgery and CLP both caused significant increases in C5a 
compared to untreated control (C) mice (p<0.05); however, differences in C5a after CLP or sham 
surgery were not significant for either genotype, nor between genotypes. Plasma levels of KC (B), 
MCP-1 (C), and MIP-2 (D) at various time points after CLP.  
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various leukocyte subsets [neutrophils (Figure 21B), lymphocytes (Figure 21C), and 
monocytes (Figure 21D]. Notably, there was a significant increase in lymphocyte infiltration 
above baseline in WT mice (baseline 6  0.5 X 103 cells, 24 hrs. post-CLP 14  4 X 103 
cells, p=0.008) that was not observed in FXI-/- mice (baseline 6 ± 0.7 X 103 cells, 24 hrs. 
post-CLP 8 ± 1 X 103 cells, p=0.2) (Figure 21C).  Taken as a whole, the data do not support 
a clear influence of FXI on leukocyte migration after CLP, but do introduce the possibility 
that lymphocyte response may be more robust in WT mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Peritoneal leukocyte infiltration after CLP.  Leukocyte counts in fluid aspirated 
after peritoneal wash with 5ml NaCl, 2mM EDTA, as measured by an automated hematology 
analyzer (Hemavet 950FS).  Data are from 24 hours after CLP in WT (black bars) and FXI-/- 
(white bars) mice compared to untreated controls (noted by the letter “C”) and to samples 
taken 24 hours after sham (Sh) surgery.  (A) Total leukocyte counts were significantly greater 
than control for both WT (p=0.0007) and FXI-/- (p=0.0002) mice. This was also true for (B) 
neutrophils and (D) monocytes. However, only WT mice had a significant elevation in 
lymphocyte counts (*p=0.0008) compared to controls. For all panels, error bars represent 
SEM. 
 
77 
 
Evaluation of microorganisms during CLP-induced sepsis.  
As mortality after CLP has been associated with bacteremia (Cuenca, Delano et al. 
2010), we performed aerobic and anaerobic CFU counts on blood collected 24 hours after 
CLP or sham surgery in groups of 6 mice to see if differences in the level of bacteremia 
might explain the survival difference between WT and FXI-/- mice.  No bacteria were 
cultured from blood obtained from either group after sham surgery, while 4 of 6 WT and 6 
of 6 FXI-/- mice had positive cultures for either aerobic or anaerobic bacteria 24 hours after 
CLP.  There was no difference in CFU counts between WT and FXI-/- mice in this study 
(Figure 22).   
 
 
 
 
 
 
 
 
Figure 22. Evaluation of microorganisms during CLP-induced sepsis. Whole blood obtained 24 
hours post-CLP or sham surgery was diluted 1:10 in pre-reduced anaerobically sterilized (PRAS) 
media (Anaerobe Systems, Morgan Hill, CA) (Hyde, Stith et al. 1990) for aerobic and anaerobic 
bacteria colony forming unit (CFU) counts. Samples were processed by 10-fold serial dilution in PBS, 
pH 7.00. Aliquots (100 l) of each dilution were plated on BBL™ Columbia Sheep Blood Agar 
(SBA), BBL™ CDC Anaerobic SBA, and BBL™ CDC Anaerobic SBA with kanamycin and 
vancomycin. Columbia SBA was incubated aerobically at 35.0 C, while other plates were incubated 
anaerobically at 35.0 C for 48 hours. CFU counts were recorded for plates containing 30-300 CFUs.  
Data are presented as combined aerobic and anaerobic CFU counts in WT and FXI-/- mice.  There were 
diff i C b b d d d i i
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CHAPTER VI 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Factor XI is at a Junction Between Coagulation and Inflammation 
 The primary finding of this work is that FXI influences systemic inflammation 
during murine polymicrobial sepsis through mechanisms that are not exclusively related to 
thrombin generation, a finding that has not been reported to our knowledge.  We present 
compelling evidence that suggests this influence is at least partly due to an effect on contact 
activation.  Taken together with our earlier findings that assigned a more “traditional” role 
for FXI in sepsis-induced DIC, the accumulated data place FXI at a junction between pro-
inflammatory and pro-coagulant mechanisms, where it is positioned to contribute to either or 
both, depending on the nature of the insult.  Figure 23 summarizes the various mechanisms 
by which FXI may influence the two pathways.  First, FXI is a component of the thrombin 
generating mechanism that is triggered during hemostasis (Figure 23, panel 1).  Here, FXI 
is activated by thrombin, and the resulting FXIa cleaves FIX to sustain thrombin production 
by participating in a feedback loop.  Thrombin generation may ultimately amplify the 
inflammatory response by, for example, enhancing cytokine production through PAR 
cleavage on vascular endothelial cells and leukocytes (Figure 23, panel 3). FXIa could also 
serve as a bridge between contact activation and thrombin generation (Figure 23, panel 2).  
In this case, FXIa is generated during contact activation on polyanions (such as platelet or 
bacterial polyphosphates, and nucleic acids) and bacterial surfaces, where it then exerts a 
procoagulant effect by cleaving FIX.  Our results indicate that FXIa also indirectly 
contributes to inflammation by promoting the activation of the contact proteins FXII and PK, 
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Figure 23. FXI in thrombin generation and contact activation during sepsis. Thrombin 
Generation (Panel 1). Depicted are proteolytic reactions that generate thrombin at a site of vascular 
injury. The process is initiated by activation of factors X and IX by the factor VIIa/tissue factor (TF) 
complex. Vitamin-K dependent protease zymogens are shown in black type with the active protease 
forms indicated by a lower case “a”. The blue ovals represent cofactors. During hemostasis, FXI is 
converted to FXIa by thrombin (white arrow). FXIa then activates FIX (yellow arrow). Contact 
activation (Panel 2). On a surface, FXII and PK undergo reciprocal activation to FXIIa and -kal. HK 
serves as a cofactor for this reaction. FXIIa can promote thrombin generation by activating FXI 
(green arrow).  -kal cleaves HK liberating bradykinin (BK) and antimicrobial peptides (AMPs). 
FXIa, can also contribute to contact activation through activation of FXII (gray arrow). Panels A and 
B list factors that could trigger or enhance thrombin generation (A) or contact activation (B). Panels 
3, 4, and 5 list processes mediated by thrombin (3), FXIIa and HKa (4) or -kal (5) that could 
contribute to sepsis.  Panel 6 lists some of the consequences of those processes. 
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perhaps resulting in BK-mediated vasodilation and tissue edema, as well as cytokine release 
(Figure 23, panels 4 and 5). 
 
Future Studies 
More work is needed to dissect the precise role of FXIa in cytokine release and 
inflammation, particularly considering earlier data, which suggest there are FXIIa-
independent mechanisms through which FXI/FXIa operates.  Host responses in WT mice 
treated with the anti-FXI monoclonal antibody 14E11, which blocks activation of FXI by 
FXIIa (Kravtsov, Matafonov et al. 2009), were not identical to those of FXI deficient mice 
after CLP or infection with lethal doses of L. monocytogenes (Tucker, Gailani et al. 2008, 
Luo, Szaba et al. 2012, Tucker, Verbout et al. 2012).  FXI deficient mice had a survival 
advantage compared to WT mice after inoculation with high concentrations of L. 
monocytogenes, but pre-treatment of WT mice with 14E11 was only protective in similarly-
infected mice when sub-therapeutic doses of ampicillin were given (Luo, Szaba et al. 2012).  
One explanation for this is that FXI participates in host defense through mechanisms that do 
not involve contact activation.  One mechanism may be through a direct effect on leukocyte 
trafficking, especially considering that peritoneal leukocyte counts were significantly lower 
in FXI-/- mice compared to WT mice 24 hours after low-grade CLP (Tucker, Gailani et al. 
2008), but not in CLP-operated WT mice after pre-treatment with 14E11 (Tucker, Verbout et 
al. 2012).  This introduces the possibility that FXI alters neutrophil migration in a FXIIa-
independent manner.  FXI binds to neutrophils, and may affect neutrophil chemotaxis 
(Itakura, Verbout et al. 2011) and activation (Coomber, Galligan et al. 1997).  Although our 
current study does not indicate a clear influence of FXI on leukocyte migrate into the 
peritoneum, they do show a non-significant increase in the various leukocyte subsets in WT 
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mice compared to their FXI-/- littermates.  We used an automated cell counter to determine 
peritoneal leukocyte counts and obtained results that, although inconclusive, do not rule out 
a role for FXI in leukocyte migration.  With this in mind, future studies should employ flow 
cytometry to more accurately determine peritoneal levels of both the myeloid (monocytes, 
macrophages, and neutrophils) and lymphoid (CD4+ T cells, CD8+ T cells, NK cells, etc.) 
leukocyte populations.   
 Our work does not exclude the possibility that FXI activation through the extrinsic 
(TF) pathway contributes to pathology during sepsis.  The CLP model does not cause overt 
DIC in mice in our hands, but it is still possible that pathology from thrombin-mediated FXI 
activation occurs.  To further investigate this possibility, WT and FXI-/- mice should be 
compared with FXII-/- and PK-/- mice in the CLP model to determine the influence of these 
proteins on survival, thrombin generation, inflammation (measurement of plasma cytokines 
and SAP, and peritoneal leukocyte counts), and bacterial dissemination.  If survival rates 
after CLP are comparable among FXI-/-, FXII-/-, and PK-/- animals, we may conclude that 
contact activation-induced FXI activation is largely responsible for the mortality observed in 
WT mice.  An observation of improved survival in FXI-/- mice relative to FXII-/- and PK-/- 
mice would suggest a more complex pathophysiology.  It could indicate that FXI activation 
is mediated through additional mechanisms, such as the TF pathway, and/or, that FXII and 
PK are more important, relative to FXI, for the mounting of an effective host defense against 
infection. Time course studies should follow the survival experiments so that the complex 
host responses that contribute to morbidity and mortality during CLP-induced sepsis may be 
further understood.   For example, if mortality in FXII-/- or PK-/- results from increased 
susceptibility to infection, we may expect to see elevated peritoneal and blood levels of 
bacteria in these animals.    
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Clinical relevance  
The clinical relevance of this work remains to be determined.  Most sepsis therapies 
that have shown promise in animal models do not advance to clinical trials, and those that do 
often fail to show a benefit in humans (Deitch 1998).  Anticoagulants are certainly no 
exception to this trend.  In the most recent update to the International Guidelines for the 
Management of Severe Sepsis and Septic Shock (Dellinger, Levy et al. 2013), heparin 
therapy for thrombus prophylaxis is the only recommended anticoagulant strategy, but this 
therapy can only be used in septic patients that are not experiencing a coagulopathy.  The 
present study did not reproduce the apparent coagulopathy that was observed in previous 
work with the CLP model (Tucker, Gailani et al. 2008, Tucker, Verbout et al. 2012).  
However, the earlier studies, along with studies with mouse thrombosis models, do suggest 
that targeting FXI may be safer than using heparin when treating patients that are in DIC.   
Considering this, the major advantage of FXI as a target for sepsis therapy over other 
anticoagulant strategies may be its ability to “first, do no harm.”  
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APPENDIX 
VALIDATION OF THE CECAL LIGATION AND PUNCTURE MODEL FOR 
EVALUATING THE CONTRIBUTION OF FXI DURING MURINE SEPSIS 
 
 
Introduction 
 A multitude of animal sepsis models are described in the literature.  These models 
have been divided into three categories: exogenous administration of a viable pathogen (e.g., 
a bacteria), exogenous administration of a toxin (e.g. LPS), or techniques that alter the 
permeability of the bowel (e.g., CLP) (Buras, Holzmann et al. 2005).  Of these, CLP most 
closely mimics the hemodynamic and cytokine response observed in humans with sepsis, 
(Wichterman, Baue et al. 1980, Deitch 1998, Buras, Holzmann et al. 2005, Hubbard, 
Choudhry et al. 2005, Dyson and Singer 2009, Dejager, Pinheiro et al. 2011), probably 
because it provides a continuous source of endogenous gut flora instead of a massive bolus 
of laboratory strains of bacteria or toxin (Deitch 1998).  Additionally, because sepsis in 
humans typically arises from a local infection that subsequently becomes systemic (Freise, 
Bruckner et al. 2001), the infection that is induced by CLP is also considered to be more 
clinically relevant.  Considering this, we chose the CLP model to evaluate the role of FXI 
during sepsis.  This model was new to our laboratory, requiring us to perform several 
preliminary studies.  These studies in WT C57Bl/6 mice allowed us to refine our technique 
(and thus improve reproducibility), evaluate survival after CLP, and identify which 
inflammatory mediators change reliably during sepsis.  The pilot studies also helped us to 
gain insight into any histologic changes that are apparent during sepsis.   
Our pilot studies of WT C57Bl/6 mice featured an in-depth examination of the 
cytokine response, along with a cursory examination of the impact of CLP on the 
coagulation system.  Of note is that we examined a greater range of time points (2, 4, 8, 12, 
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24, and 48 hours after CLP) in the pilot study, while we limited our investigations to 4, 8, 
and 24 hours after CLP in the full time course study.  Pilot studies were conducted using 
low-grade CLP as, at this stage in our investigation, we had yet to discover that FXI-/- mice 
only exhibited a survival advantage after high-grade CLP in our hands.  Indeed, this 
observation is what led us to use high-grade CLP in follow-on time course studies, and 
contributed to our decision to limit the latter studies to the first 24 hours of CLP-induced 
sepsis.  Our survival studies predicted that a large proportion of animals would succumb to 
sepsis within 48 hours after high-grade CLP, so that too few animals would be available for 
investigating the inflammatory and coagulation system response at this stage of sepsis.  The 
lower grade of injury in the pilot study may have resulted in a disease process that was 
different than what we observed with high grade injury (Rittirsch, Huber-Lang et al. 2009), 
but it did allow us to look at changes at a later time point than in the full study.  Histology 
findings at 24 hours after high-grade CLP in the full study were largely unremarkable, but 
we were able to see significant changes in tissue histology at 48 hours after low-grade CLP 
in the pilot study.   Of note is that we saw no clear evidence of DIC, even at 48 hours, in this 
model. This appendix includes a brief review of CLP, followed by some interesting findings 
from our preliminary work. 
 
Cecal Ligation and Puncture 
CLP was introduced by Wichterman and colleagues, who first used the technique to 
induce polymicrobial sepsis in rats (Wichterman, Baue et al. 1980). The procedure, which is 
described in Figure 24 and in the Materials and Methods section of Chapter IV, involves 
ligation of the cecum below the ileocecal valve after midline celiotomy, followed by 
puncture of the organ with a hypodermic needle (Rittirsch, Huber-Lang et al. 2009).   It is a 
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modification of a procedure, cecal ligation, that was originally used to study sepsis in dogs 
(Clowes, Zuschneid et al. 1968) and pigs (Imamura and Clowes 1975).  Although Ryan et 
al., who adapted the model for use in laboratory rodents, observed peritonitis in rats after 
cecal ligation (Ryan, Blackburn et al. 1974),  Wichterman added the “P” (puncture) to “CL” 
(cecal ligation) after failing to induce peritonitis and death (no deaths among 71 rats) with 
cecal ligation alone.  The procedure is now in common use in mice as well as rats, and has 
also been described in neonatal piglets (Kato, Hussein et al. 2004) and sheep (Richmond, 
Walker et al. 1985).   
 
 
 
 
 
 
Figure 24.  Cecal ligation and puncture procedure.  (A).  Photograph of the murine distal ileum, 
cecum, and proximal ascending colon.  The yellow line indicates a ligature location that induces a high 
grade of sepsis; the white line indicates a ligature location that induces a low-grade sepsis.  Surgery is 
initiated through a midline celiotomy (B).  The cecum is located and exteriorized (C), then ligated 
according to the desired level of severity and punctured (D).  The abdomen is closed with a simple 
continuous suture pattern, and the skin is closed with wound clips (E).  The surgery takes 
approximately 10-15 minutes.  The image shown in panel F is a necropsy photograph showing the 
cecum after high-grade CLP.   
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Microfil Experiments 
 
There are many factors that affect morbidity and mortality in the CLP model of 
experimental sepsis, such as amount of cecum ligated, needle gauge used for cecal 
perforations, and number of perforations (Singleton and Wischmeyer 2003, Rittirsch, Huber-
Lang et al. 2009).  It is important to conduct the CLP surgeries in a systematic manner to 
reduce variability.  To accomplish this, we used the same surgeon (the author) for all CLP 
procedures, and refined our surgical technique, specifically the cecal ligation portion of CLP, 
using experiments with Microfil (MV-122 Flow Tech Inc., Carver, MA).  This allowed us to 
evaluate the cecal microcirculation of mice subjected to cecal ligation (no puncture) to assess 
the effectiveness of our ligation.  Microfil is a compound that fills and opacifies blood 
vessels, allowing the user to visualize the microcirculation (http://www.flowtech-
inc.com/microfil.htm).  Because the goal of the procedure is to cut off circulation to the 
affected portion of the organ, we reasoned that an effective ligation would result in no 
Microfil infiltration distal to the ligation.  We conducted a small study (Figure 25) where we 
ligated two mice with the “traditional” method (suture), and two mice with metallic vascular 
clips.  One control mouse, in which no ligation was performed, was used for comparison.  
After euthanasia, mice were perfused with Microfil as previously described (Yuasa, 
Mignemi et al. 2014) (methods summarized in the figure legend).  Microvascular infiltration 
of Microfil was evident in the control mouse (Figure 25A).  The vascular clips (Figure 25B) 
did not prevent infiltration of Microfil, indicating that this method is not an effective means 
of achieving tissue ischemia.  Interestingly, we noted a difference in the degree of blood 
vessel occlusion between the two suture-ligated mice.  One mouse (Figure 25C) displayed 
complete tissue ischemia, with no Microfil infiltration noted distal to the ligature.  This 
indicated that our ligature successfully occluded both arteries and veins.  In the other mouse, 
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however, it was evident that the suture had been place inappropriately.  In this mouse 
(Figure 25D), the cecum was engorged with blood distal to the ligation and a small amount 
of Microfil infiltration was observed, indicating that we had left the arterial circulation intact 
while rendering the veins unable to drain blood out of the organ.  We determined that this 
difference was likely due to variability in the method we used to tighten our ligatures.  We 
had previously experienced premature breakage of the suture if we grasped one end of the 
knot with a needle holder (surgical instrument) while tightening the ligature.  This likely led 
to differences in the tightening pressure applied to avoid breakage.  The results of the 
Microfil experiments led us to tighten our ligatures by hand, which did not result in ligature 
breakage, even when sutures were applied very firmly.  We feel that this modification to our 
technique further reduced variability in our model.  
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Figure 25.  Microfil experiments.  Two hours after cecal ligation, mice were euthanized and a ventral 
midline incision extending from the thoracic inlet to the caudal abdomen was made.  The thorax and 
abdomen were opened and a 25G butterfly catheter was placed in the left ventricle of the heart and glued 
in place.  The caudal vena cava was transected proximal to the liver and approximately 9ml of warm 
heparinized saline was flushed through the butterfly catheter and vasculature.  The vasculature was then 
perfused with a 10% solution of buffered neutral formalin, then injected with 3ml of Microfil contrast 
polymer.  The control mouse exhibited complete perfusion of contrast polymer throughout the cecal 
microvasculature (A), while the metallic vascular clips failed to prevent Microfil infiltration (B).  The 
suture ligation in one mouse (C) effectively prevented all Microfil infiltration.  In contrast, some 
Microfil infiltration was noted in the other suture ligated mouse (D).  Additionally, the cecum of this 
mouse was engorged with blood, indicating that the cecal ligation had left the arterial circulation intact 
while blocking venous drainage, thereby allowing blood to pool within the organ before euthanasia. 
Microfil experiments were performed by Dr. Nicholas Mignemi, who also provided the images shown.      
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Figure 26.  Markers of inflammation after CLP-pilot studies.  Blood was collected from WT 
C57BL/6 mice at the indicated times after CLP.  Plasma cytokine and chemokine (A & B) and 
SAP (D) levels were measured with a Luminex assay.  Leukocyte counts in peritoneal wash fluid 
were measured with an automated hematology analyzer (C). There were significant increases in 
peritoneal leukocyte (p= 0.02) and SAP (p=0.03) levels starting at 24 hours post-CLP. 
 
Pilot studies 
We conducted a pilot time course study of WT mice to evaluate the feasibility of our 
sample collection strategy and experimental technique for follow-on work, and to determine 
the optimum time points for collection.  We collected samples from groups of mice at 2, 4, 8, 
12, 24, and 48 hours after CLP to evaluate markers of inflammation and coagulopathy.  For 
the cytokine and chemokine markers, we constructed simple XY plots with each point 
representing the mean levels from 3 or 4 mice (no error bars shown), and lines drawn 
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Figure 27.  FXI levels and platelet counts after CLP-pilot studies. CLP was conducted on 
groups of 4 male, 4-month-old C57BL/6 mice at the indicated time points, and blood was collected 
by cardiac puncture.   (A)  Plasma factor XI levels.  (B) Platelet counts, measured with an 
automated hematology analyzer. * p=0.03.    
 
between points to more easily identify the time points that would yield the most information 
in further studies.  Figure 26A shows mean levels of IL-6, IL-10, MIP-2, KC, and MCP-1.  
(Note: levels of these markers exceeded the maximum limit of detection (20,000 pg/ml) for 
the assay).  Figure 26B shows mean levels of IL-1 beta and TNFα. We also measured 
peritoneal leukocyte counts (Figure 26C) and plasma SAP (Figure 26D) in these mice, and 
found significant increases beginning at 24 hours after CLP.  These data confirmed that the 
markers we chose were useful for gauging the inflammatory response after CLP.   
We then evaluated FXI levels by ELISA because of an earlier finding that showed 
elevated FXI mRNA after infection (Luo, Szaba et al. 2011).  In contrast to the earlier study, 
FXI levels decreased modestly, though not significantly, in the 48 hours after CLP (Figure 
27A). Mean platelet counts were moderately decreased from baseline (not significantly) 
between 4 and 24 hours, and were significantly lower than baseline at 48 hours (p=0.03) 
(Figure 27B).   
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 We evaluated hematoxylin and eosin stained sections of several organs (liver, 
kidney, spleen, heart, and brain) taken from WT mice at 48 hours after CLP surgery to look 
for evidence of inflammation, bacterial dissemination, or DIC.  We observed a number of 
histologic lesions, but, notably, we did not see obvious evidence of thrombosis. 
Microhemorrhage with perivascular inflammation and edema was commonly observed 
within brain tissue collected from WT mice (Figures 28A and 28B).  A photograph of brain 
section from a control (no surgery) mouse is provided in figure 28C for comparison.   
 
 
 
Histologic evaluation of spleen provided additional information on the inflammatory 
course of disease.  In samples taken from WT mice 48 hours post-CLP, we observed severe 
congestion and white pulp depletion of the spleen with lymphoid apoptosis (Figures 29A 
and 29B), suggestive of acute bacteremia (Carlton, McGavin et al. 1995).  This contrasts 
with the marked hyperplasia of splenic white pulp that was observed in a mouse that 
survived the 7-day study period of an earlier survival pilot experiment (Figure 29E).  
Figure 28.  Histology of brain tissue-pilot studies.  Photomicrographs (400X magnification) of 
paraffin embedded sections of brain stained with hematoxylin and eosin. (A&B) mice 48 hours after 
CLP and control mouse that did not undergo surgery (C).   (A) Microhemorrhages are commonly 
observed throughout the brain(arrows).  Perivascular inflammation and edema are also present (B, 
arrows) This is not observed in the control brain (C).  
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Figure 29.  Lymphoid response to CLP in pilot studies.  Photomicrographs of 
paraffin embedded sections of spleen stained with hematoxylin and eosin.  Images A, C, 
& E are 40X; images B, D, & F are 400X.  48 hours after CLP, splenic sections from a 
WT mouse show depletion of the white pulp, while the red pulp is expanded by 
congestion (A).  Apoptosis of lymphocytes is prominent in the white pulp (arrows) (B).  
Images C and E are of a non-operated WT control mouse.  Images E and F are from a 
FXI-/- mouse that was still alive at the end of a 7-day pilot survival study.  There is 
hyperplasia of the white pulp (E), and the red pulp is expanded by extramedullary 
hematopoiesis.   
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Perhaps the most striking finding from the histological evaluation of mouse organs 
48 hours after CLP was the clear evidence of bacterial dissemination. Figures 30A and 30B 
show heavy bacterial colonization of the surface of the liver, along with areas of hepatic 
necrosis, while the photograph in Figure 30F shows bacterial dissemination to a thoracic 
lymph node with concurrent apoptosis of lymphocytes.  Figures 30C and 30D are 
photographs of a liver section from a mouse that survived to 7 days, and are similar to 
images from a control mouse (not shown).     
 
 
 
 
Figure 30.  Evidence of bacterial dissemination after CLP-pilot studies.  H&E stained sections of 
paraffin-embedded liver (A-D) and thoracic lymph node (E & F).  Images A, C, and E are 40X, while 
images B, D, and F are 400X.  48 hours after CLP, the surface of the liver is heavily colonized with 
bacteria (arrows) and there are areas of hepatic necrosis (asterisks) (A & B).  This is not observed in 
a mouse that survived to 7 days after CLP (C & D).  Images E and F show bacterial dissemination to 
thoracic lymph node (arrows in image F) and apoptotic bodies (asterisks in image F) that are 
indicative of apoptosis of lymphocytes. 
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Discussion 
Given the results from earlier work with the CLP model (Tucker, Gailani et al. 
2008), as well as our understanding of the role of FXI in thrombosis, we were somewhat 
surprised to find no evidence of thrombosis in our pilot studies of WT mice.  We initially 
postulated that the microhemorrhage observed in some brain sections of WT mice 48 hours 
after CLP could indicate that mice were entering the latter stages of DIC, wherein 
hemorrhage predominates.  In retrospect, this now seems unlikely.  First, we did not see 
evidence of hemorrhage at necropsy or during the histologic evaluation of other organs.  
Second, mean platelet counts remained above 200,000 cells/µl, with a count of 172,000 
cells/µl being the lowest observed.  Using a tail bleeding time assay, Morowski and 
colleagues recently demonstrated that platelet counts as low as 25,000 cells/µl are adequate 
for supporting normal hemostasis in C56BL/6 mice (Morowski, Vogtle et al. 2013).  The 
levels we observed were at least 8-fold higher than this, suggesting that the observed 
hemorrhage in mouse brains was not a result of platelet consumption secondary to DIC.  
This notion is reinforced by the findings from our published study of WT and FXI-/- mice 
(Bane, Ivanov et al. 2016), which utilized a broader array of markers of DIC (TAT and 
fibrinogen levels, platelet counts, and histology) and showed no evidence of DIC in mice of 
either genotype at 24 hours after CLP.  Considering this, we are inclined to conclude that 
CLP, at least in our hands, is an inappropriate model for assessing DIC in mice.   
In contrast to markers of coagulopathy, we saw ample evidence of inflammation 
after CLP in our pilot studies, with elevations in numerous plasma cytokines and 
chemokines.  SAP levels rose appreciably after CLP, as did peritoneal leukocyte counts.  
The histologic findings provide compelling evidence that CLP triggered a profound 
lymphoid response, resulting in marked lymphocyte apoptosis in spleen and lymph node.  In 
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the tissue sections that we examined, the lymphoid depletion was accompanied by 
widespread bacterial dissemination, with areas of hepatocyte necrosis at 48 hours after CLP, 
suggesting that immunosuppression was the predominant feature of the disease process at 
this point.  We have no way of knowing if the animals sacrificed at 48 hours would have 
ultimately survived this insult.   We did note splenic white pulp hyperplasia and no evidence 
of bacterial dissemination or hepatocyte necrosis in a mouse that survived to 7 days after 
CLP.  Two possible scenarios for mice that survived to 7 days in pilot studies are that some 
mice (1) mounted a robust immune response that prevented bacterial dissemination 
altogether, or (2) mounted an insufficient response early on, but then recovered to clear the 
bacterial infections.   
In summary, the pilot experiments were instructive and guided many of our 
decisions for follow-on work.  Both the pilot and follow-on studies appeared to implicate the 
inflammatory response (whether it be overwhelming or insufficient) in the morbidity and 
mortality of sepsis.  However, neither study ruled out a role for FXI in the coagulopathy of 
sepsis because CLP did not result in DIC in our hands.  A different model is required to 
make this determination. 
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